UNITED
STATES


SECURITIES
AND EXCHANGE COMMISSION


Washington,
D.C. 20549





FORM
10-Q





x
            QUARTERLY
      REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
      1934





For
the quarterly period ended September 30, 2010





 ̈
            TRANSITION
      REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF
      1934





Commission
file number:  000-51476





LIXTE
BIOTECHNOLOGY HOLDINGS, INC.


(Exact
name of registrant as specified in its charter)





Delaware
            20-2903526(State
      or other jurisdiction of
            (I.R.S.
      Employerincorporation
      or organization)
            Identification
      Number)





248
Route 25A, No. 2


East
Setauket, New York 11733


(Address
of principal executive offices)





(631)
942-7959


(Registrant’s
telephone number, including area code)





Not
applicable


(Former
name, former address and former fiscal year, if changed since last
report)





Indicate
by check mark whether the registrant (1) has filed all reports required to be
filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required
to file such reports), and (2) has been subject to such filing requirements for
the past 90 days.  Yes x No  ̈





Indicate
by check mark whether the registrant has submitted electronically and posted on
its corporate Web site, if any, every Interactive Data File required to be
submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding
12 months (or for such shorter period that the registrant was required to submit
and post such files).  Yes  ̈ No  ̈





Indicate
by check mark whether the registrant is a large accelerated filer, an
accelerated filer, or a non-accelerated filer (as defined in Rule 12b-2 of the
Exchange Act).





Large
      accelerated filer  ̈
            
            Accelerated
      filer  ̈Non-accelerated
      filer  ̈
            
            Smaller
      reporting company x





Indicate
by check mark whether the registrant is a shell company (as defined in Rule
12b-2 of the Exchange Act).  Yes  ̈ No x





As of
October 29, 2010, the Company had 35,077,178 shares of common stock, $0.0001 par
value, issued and outstanding.





Documents
incorporated by reference:  None









LIXTE
BIOTECHNOLOGY HOLDINGS, INC.




TABLE
OF CONTENTS





Page
                          NumberPART
      I - FINANCIAL INFORMATIONItem
      1. Condensed Consolidated Financial StatementsCondensed
      Consolidated Balance Sheets -September
      30, 2010 (Unaudited) and December 31, 2009
                        
                        4Condensed
      Consolidated Statements of Operations (Unaudited) -Three
      Months End September 30, 2010 and 2009, Nine Months Ended September 30,
      2010 and 2009, and Period from August 9, 2005 (Inception) to September 30,
      2010 (Cumulative)
                        
                        5Condensed
      Consolidated Statement of Stockholders’ Equity (Deficiency) (Unaudited)
      -
                          August
      9, 2005 (Inception) to September 30, 2010
                        
                        6Condensed
      Consolidated Statements of Cash Flows (Unaudited) -Nine
      Months Ended September 30, 2010 and 2009, and Period from August 9, 2005
      (Inception) to September 30, 2010 (Cumulative)
                        
                        7Notes
      to Condensed Consolidated Financial Statements (Unaudited)
    -Three
      Months Ended September 30, 2010 and 2009, Nine Months Ended September 30,
      2010 and 2009, and Period from August 9, 2005 (Inception) to September 30,
      2010 (Cumulative)
                        
                        8Item
      2. Management’s Discussion and Analysis of Financial Condition and Results
      of Operations
                        
                        23Item
      3. Quantitative and Qualitative Disclosures About Market
    Risk
                        
                        31Item
      4. Controls and Procedures
                        
                        31PART
      II - OTHER INFORMATIONItem
      1. Legal Proceedings
                        
                        32Item
      1A. Risk Factors
                        
                        32Item
      2. Unregistered Sales of Equity Securities and Use of
    Proceeds
                        
                        32Item
      3. Defaults Upon Senior Securities
                        
                        32Item
      4. Reserved
                        
                        32Item
      5. Other Information
                        
                        32Item
      6. Exhibits
                        
                        32SIGNATURES
                        
                        33




2




Forward-Looking
Statements





This
Quarterly Report on Form 10-Q contains certain forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the
Securities Exchange Act of 1934. For example, statements regarding the Company’s
financial position, business strategy and other plans and objectives for future
operations, and assumptions and predictions about future product demand, supply,
manufacturing, costs, marketing and pricing factors are all forward-looking
statements. These statements are generally accompanied by words such as
“intend,” anticipate,” “believe,” “estimate,” “potential(ly),” “continue,”
“forecast,” “predict,” “plan,” “may,” “will,” “could,” “would,” “should,”
“expect” or the negative of such terms or other comparable terminology. The
Company believes that the assumptions and expectations reflected in such
forward-looking statements are reasonable, based on information available to it
on the date hereof, but the Company cannot provide assurances that these
assumptions and expectations will prove to have been correct or that the Company
will take any action that the Company may presently be planning. However, these
forward-looking statements are inherently subject to known and unknown risks and
uncertainties. Actual results or experience may differ materially from those
expected or anticipated in the forward-looking statements. Factors that could
cause or contribute to such differences include, but are not limited to,
regulatory policies, available cash, research and development results,
competition from other similar businesses, and market and general economic
factors. This discussion should be read in conjunction with the condensed
consolidated financial statements and notes thereto included in Item 1 of this
Quarterly Report on Form 10-Q.




3




PART
I - FINANCIAL INFORMATION





ITEM
1. 
           CONDENSED
CONSOLIDATED FINANCIAL STATEMENTS





LIXTE
BIOTECHNOLOGY HOLDINGS, INC. AND SUBSIDIARY


(a
development stage company)





CONDENSED
CONSOLIDATED BALANCE SHEETS





September
                                  30,
                                  2010
                                
                                
                                December
                                  31,
                                  2009(Unaudited)ASSETSCurrent
      assets:Cash
                                
                                $
                                123,089
                                
                                
                                $
                                1,543,991Money
      market funds
                                
                                
                                1,800,822
                                
                                
                                
                                25,000Advances
      on research and development contract services
                                
                                
                                —
                                
                                
                                
                                5,000Prepaid
      expenses and other current assets
                                
                                
                                35,966
                                
                                
                                
                                27,354Total
      current assets
                                
                                $
                                1,959,877
                                
                                
                                $
                                1,601,345LIABILITIES
      AND STOCKHOLDERS’ EQUITYCurrent
      liabilities:Accounts
      payable and accrued expenses
                                
                                $
                                21,383
                                
                                
                                $
                                83,546Research
      and development contract liabilities
                                
                                
                                51,679
                                
                                
                                
                                50,000Liquidated
      damages payable under registration rights agreement
                                
                                
                                74,000
                                
                                
                                
                                74,000Due
      to stockholder
                                
                                
                                92,717
                                
                                
                                
                                92,717Total
      current liabilities
                                
                                
                                239,779
                                
                                
                                
                                300,263Commitments
      and contingenciesStockholders’
      equity:Preferred
      stock, $0.0001 par value; authorized – 10,000,000 shares; issued –
      None
                                
                                
                                —
                                
                                
                                
                                —Common
      stock, $0.0001 par value; authorized - 100,000,000 shares; issued and
      outstanding - 35,077,178 shares and 30,502,178 shares at September 30,
      2010 and December 31, 2009, respectively
                                
                                
                                3,508
                                
                                
                                
                                3,050Advances
      under equity financing
                                
                                
                                —
                                
                                
                                
                                1,200,000Additional
      paid-in capital
                                
                                
                                7,804,032
                                
                                
                                
                                5,147,583Deficit
      accumulated during the development stage
                                
                                
                                (6,087,442
                                )
                                
                                
                                (5,049,551
                                )Total
      stockholders’ equity
                                
                                
                                1,720,098
                                
                                
                                
                                1,301,082Total
      liabilities and stockholders’ equity
                                
                                $
                                1,959,877
                                
                                
                                $
                                1,601,345





See
accompanying notes to condensed consolidated financial statements.




4




LIXTE
BIOTECHNOLOGY HOLDINGS, INC. AND SUBSIDIARY


(a
development stage company)





CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)





Period from
                                          August 9,
                                          2005
                                          (Inception) toThree Months Ended
                                          September 30,
                                        
                                        
                                        Nine Months Ended
                                          September 30,
                                        
                                        
                                        September 30,
                                          20102010
                                        
                                        
                                        2009
                                        
                                        
                                        2010
                                        
                                        
                                        2009
                                        
                                        
                                        (Cumulative)Revenues
                                        
                                        $
                                        —
                                        
                                        
                                        $
                                        —
                                        
                                        
                                        $
                                        —
                                        
                                        
                                        $
                                        —
                                        
                                        
                                        $
                                        —Costs
      and expenses:General
      and administrative costs, including $194,493 and $231,282 of stock-based
      compensation costs for the three months ended September 30, 2010 and 2009,
      respectively, $287,767 and $306,692 of stock-based compensation costs for
      the nine months ended September 30, 2010 and 2009, respectively, and
      $2,379,578 of stock-based compensation costs for the period from August 9,
      2005 (inception) to September 30, 2010 (cumulative)
                                        
                                        
                                        246,037
                                        
                                        
                                        
                                        300,850
                                        
                                        
                                        
                                        511,506
                                        
                                        
                                        
                                        555,743
                                        
                                        
                                        
                                        3,681,241Depreciation
                                        
                                        
                                        —
                                        
                                        
                                        
                                        —
                                        
                                        
                                        
                                        —
                                        
                                        
                                        
                                        128
                                        
                                        
                                        
                                        1,909Research
      and development costs, including $63,513 and $19,236 of stock-based costs
      for the three months ended September 30, 2010 and 2009, respectively,
      $81,640 and $116,835 of stock-based costs for the nine months ended
      September 30, 2010 and 2009, respectively, and $478,470 of stock-based
      costs for the period from August 9, 2005 (inception) to September 30, 2010
      (cumulative) (stock-based research and development costs include $6,250,
      $11,458 and $11,458 to a related party for the three months ended
      September 30, 2010, the nine months ended September 30, 2010, and for the
      period from August 9, 2005 (inception) to September 30, 2010 (cumulative),
      respectively)
                                        
                                        
                                        132,656
                                        
                                        
                                        
                                        152,235
                                        
                                        
                                        
                                        527,634
                                        
                                        
                                        
                                        419,341
                                        
                                        
                                        
                                        2,304,939Reverse
      merger costs
                                        
                                        
                                        —
                                        
                                        
                                        
                                        —
                                        
                                        
                                        
                                        —
                                        
                                        
                                        
                                        —
                                        
                                        
                                        
                                        50,000Total
      costs and expenses
                                        
                                        
                                        378,693
                                        
                                        
                                        
                                        435,085
                                        
                                        
                                        
                                        1,039,140
                                        
                                        
                                        
                                        975,212
                                        
                                        
                                        
                                        6,038,089Loss
      from operations
                                        
                                        
                                        (378,693
                                        )
                                        
                                        
                                        (435,085
                                        )
                                        
                                        
                                        (1,039,140
                                        )
                                        
                                        
                                        (975,212
                                        )
                                        
                                        
                                        (6,038,089
                                        )Interest
      income
                                        
                                        
                                        700
                                        
                                        
                                        
                                        31
                                        
                                        
                                        
                                        1,249
                                        
                                        
                                        
                                        83
                                        
                                        
                                        
                                        27,116Interest
      expense
                                        
                                        
                                        —
                                        
                                        
                                        
                                        —
                                        
                                        
                                        
                                        —
                                        
                                        
                                        
                                        (452
                                        )
                                        
                                        
                                        (2,469
                                        )Liquidated
      damages under registration rights agreement
                                        
                                        
                                        —
                                        
                                        
                                        
                                        —
                                        
                                        
                                        
                                        —
                                        
                                        
                                        
                                        —
                                        
                                        
                                        
                                        (74,000
                                        )Net
      loss
                                        
                                        $
                                        (377,993
                                        )
                                        
                                        $
                                        (453,054
                                        )
                                        
                                        $
                                        (1,037,891
                                        )
                                        
                                        $
                                        (975,581
                                        )
                                        
                                        $
                                        (6,087,442
                                        )Net
      loss per common share - basic and diluted
                                        
                                        $
                                        (0.01
                                        )
                                        
                                        $
                                        (0.02
                                        )
                                        
                                        $
                                        (0.03
                                        )
                                        
                                        $
                                        (0.03
                                        )Weighted
      average common shares outstanding - basic and diluted
                                        
                                        
                                        35,077,178
                                        
                                        
                                        
                                        29,458,156
                                        
                                        
                                        
                                        34,621,134
                                        
                                        
                                        
                                        29,054,705





See
accompanying notes to condensed consolidated financial statements.




5




LIXTE
BIOTECHNOLOGY HOLDINGS, INC. AND SUBSIDIARY


(a
development stage company)





CONDENSED
CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY (DEFICIENCY)





Period
from August 9, 2005 (Inception) to September 30, 2010





Common Stock
                                      
                                      
                                      Advances
                                        Under
                                        Equity
                                      
                                      
                                      Additional
                                        Paid-in
                                      
                                      
                                      Deficit
                                        Accumulated
                                        During the
                                        Development
                                      
                                      
                                      Total
                                        Stockholders’
                                        EquityShares
                                      
                                      
                                      Amount
                                      
                                      
                                      Financing
                                      
                                      
                                      Capital
                                      
                                      
                                      Stage
                                      
                                      
                                      (Deficiency)Balance,
      August 9, 2005 (inception)
                                      
                                      
                                      —
                                      
                                      
                                      $
                                      —
                                      
                                      
                                      $
                                      —
                                      
                                      
                                      $
                                      —
                                      
                                      
                                      $
                                      —
                                      
                                      
                                      $
                                      —Shares
      issued to founding stockholder
                                      
                                      
                                      19,021,786
                                      
                                      
                                      
                                      1,902
                                      
                                      
                                      
                                      —
                                      
                                      
                                      
                                      (402
                                      )
                                      
                                      
                                      —
                                      
                                      
                                      
                                      1,500Net
      loss
                                      
                                      
                                      —
                                      
                                      
                                      
                                      —
                                      
                                      
                                      
                                      —
                                      
                                      
                                      
                                      —
                                      
                                      
                                      
                                      (16,124
                                      )
                                      
                                      
                                      (16,124
                                      )Balance,
      December 31, 2005
                                      
                                      
                                      19,021,786
                                      
                                      
                                      
                                      1,902
                                      
                                      
                                      
                                      —
                                      
                                      
                                      
                                      (402
                                      )
                                      
                                      
                                      (16,124
                                      )
                                      
                                      
                                      (14,624
                                      )Shares
      issued in connection with reverse merger transaction
                                      
                                      
                                      4,005,177
                                      
                                      
                                      
                                      401
                                      
                                      
                                      
                                      —
                                      
                                      
                                      
                                      62,099
                                      
                                      
                                      
                                      —
                                      
                                      
                                      
                                      62,500Shares
      issued in private placement, net of offering costs
                                      
                                      
                                      3,555,220
                                      
                                      
                                      
                                      355
                                      
                                      
                                      
                                      —
                                      
                                      
                                      
                                      969,017
                                      
                                      
                                      
                                      —
                                      
                                      
                                      
                                      969,372Stock-based
      compensation costs
                                      
                                      
                                      —
                                      
                                      
                                      
                                      —
                                      
                                      
                                      
                                      —
                                      
                                      
                                      
                                      97,400
                                      
                                      
                                      
                                      —
                                      
                                      
                                      
                                      97,400Net
      loss
                                      
                                      
                                      —
                                      
                                      
                                      
                                      —
                                      
                                      
                                      
                                      —
                                      
                                      
                                      
                                      —
                                      
                                      
                                      
                                      (562,084
                                      )
                                      
                                      
                                      (562,084
                                      )Balance,
      December 31, 2006
                                      
                                      
                                      26,582,183
                                      
                                      
                                      
                                      2,658
                                      
                                      
                                      
                                      —
                                      
                                      
                                      
                                      1,128,114
                                      
                                      
                                      
                                      (578,208
                                      )
                                      
                                      
                                      552,564Shares
      issued in private placement, net of offering costs
                                      
                                      
                                      999,995
                                      
                                      
                                      
                                      100
                                      
                                      
                                      
                                      —
                                      
                                      
                                      
                                      531,220
                                      
                                      
                                      
                                      —
                                      
                                      
                                      
                                      531,320Stock-based
      compensation costs
                                      
                                      
                                      250,000
                                      
                                      
                                      
                                      25
                                      
                                      
                                      
                                      —
                                      
                                      
                                      
                                      890,669
                                      
                                      
                                      
                                      —
                                      
                                      
                                      
                                      890,694Stock-based
      research and development costs
                                      
                                      
                                      —
                                      
                                      
                                      
                                      —
                                      
                                      
                                      
                                      —
                                      
                                      
                                      
                                      50,836
                                      
                                      
                                      
                                      —
                                      
                                      
                                      
                                      50,836Net
      loss
                                      
                                      
                                      —
                                      
                                      
                                      
                                      —
                                      
                                      
                                      
                                      —
                                      
                                      
                                      
                                      —
                                      
                                      
                                      
                                      (1,648,488
                                      )
                                      
                                      
                                      (1,648,488
                                      )Balance,
      December 31, 2007
                                      
                                      
                                      27,832,178
                                      
                                      
                                      
                                      2,783
                                      
                                      
                                      
                                      —
                                      
                                      
                                      
                                      2,600,839
                                      
                                      
                                      
                                      (2,226,696
                                      )
                                      
                                      
                                      376,926Stock-based
      compensation costs
                                      
                                      
                                      —
                                      
                                      
                                      
                                      —
                                      
                                      
                                      
                                      —
                                      
                                      
                                      
                                      357,987
                                      
                                      
                                      
                                      —
                                      
                                      
                                      
                                      357,987Stock-based
      research and development costs
                                      
                                      
                                      100,000
                                      
                                      
                                      
                                      10
                                      
                                      
                                      
                                      —
                                      
                                      
                                      
                                      213,051
                                      
                                      
                                      
                                      —
                                      
                                      
                                      
                                      213,061Net
      loss
                                      
                                      
                                      —
                                      
                                      
                                      
                                      —
                                      
                                      
                                      
                                      —
                                      
                                      
                                      
                                      —
                                      
                                      
                                      
                                      (1,271,522
                                      )
                                      
                                      
                                      (1,271,522
                                      )Balance,
      December 31, 2008
                                      
                                      
                                      27,932,178
                                      
                                      
                                      
                                      2,793
                                      
                                      
                                      
                                      —
                                      
                                      
                                      
                                      3,171,877
                                      
                                      
                                      
                                      (3,498,218
                                      )
                                      
                                      
                                      (323,548
                                      )Shares
      issued in private placements, net of offering costs
                                      
                                      
                                      2,420,000
                                      
                                      
                                      
                                      242
                                      
                                      
                                      
                                      —
                                      
                                      
                                      
                                      1,096,808
                                      
                                      
                                      
                                      —
                                      
                                      
                                      
                                      1,097,050Advances
      under equity financing
                                      
                                      
                                      —
                                      
                                      
                                      
                                      —
                                      
                                      
                                      
                                      1,200,000
                                      
                                      
                                      
                                      —
                                      
                                      
                                      
                                      —
                                      
                                      
                                      
                                      1,200,000Stock-based
      compensation costs
                                      
                                      
                                      150,000
                                      
                                      
                                      
                                      15
                                      
                                      
                                      
                                      —
                                      
                                      
                                      
                                      745,965
                                      
                                      
                                      
                                      —
                                      
                                      
                                      
                                      745,980Stock-based
      research and development costs
                                      
                                      
                                      —
                                      
                                      
                                      
                                      —
                                      
                                      
                                      
                                      —
                                      
                                      
                                      
                                      132,933
                                      
                                      
                                      
                                      —
                                      
                                      
                                      
                                      132,933Net
      loss
                                      
                                      
                                      —
                                      
                                      
                                      
                                      —
                                      
                                      
                                      
                                      —
                                      
                                      
                                      
                                      —
                                      
                                      
                                      
                                      (1,551,333
                                      )
                                      
                                      
                                      (1,551,333
                                      )Balance,
      December 31, 2009
                                      
                                      
                                      30,502,178
                                      
                                      
                                      
                                      3,050
                                      
                                      
                                      
                                      1,200,000
                                      
                                      
                                      
                                      5,147,583
                                      
                                      
                                      
                                      (5,049,551
                                      )
                                      
                                      
                                      1,301,082Shares
      issued in private placements, net of offering costs
                                      
                                      
                                      4,575,000
                                      
                                      
                                      
                                      458
                                      
                                      
                                      
                                      (1,200,000
                                      )
                                      
                                      
                                      2,287,042
                                      
                                      
                                      
                                      —
                                      
                                      
                                      
                                      1,087,500Stock-based
      compensation costs
                                      
                                      
                                      —
                                      
                                      
                                      
                                      —
                                      
                                      
                                      
                                      —
                                      
                                      
                                      
                                      287,767
                                      
                                      
                                      
                                      —
                                      
                                      
                                      
                                      287,767Stock-based
      research and development costs
                                      
                                      
                                      —
                                      
                                      
                                      
                                      —
                                      
                                      
                                      
                                      —
                                      
                                      
                                      
                                      81,640
                                      
                                      
                                      
                                      —
                                      
                                      
                                      
                                      81,640Net
      loss
                                      
                                      
                                      —
                                      
                                      
                                      
                                      —
                                      
                                      
                                      
                                      —
                                      
                                      
                                      
                                      —
                                      
                                      
                                      
                                      (1,037,891
                                      )
                                      
                                      
                                      (1,037,891
                                      )Balance,
      September 30, 2010 (Unaudited)
                                      
                                      
                                      35,077,178
                                      
                                      
                                      $
                                      3,508
                                      
                                      
                                      $
                                      —
                                      
                                      
                                      $
                                      7,804,032
                                      
                                      
                                      $
                                      (6,087,442
                                      )
                                      
                                      $
                                      1,720,098





See
accompanying notes to condensed consolidated financial statements.




6




LIXTE
BIOTECHNOLOGY HOLDINGS, INC. AND SUBSIDIARY


(a
development stage company)





CONDENSED
CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)





Nine Months Ended
                                                  September 30,
                                                
                                                
                                                Period from
                                                  August 9,
                                                  2005
                                                  (Inception) to
                                                  September 30,
                                                  20102010
                                                
                                                
                                                2009
                                                
                                                
                                                (Cumulative)Cash
      flows from operating activities:Net
      loss
                                                
                                                $
                                                (1,037,891
                                                )
                                                
                                                $
                                                (975,581
                                                )
                                                
                                                $
                                                (6,087,442
                                                )Adjustments
      to reconcile net loss to net cash used in operating
      activities:Depreciation
                                                
                                                
                                                —
                                                
                                                
                                                
                                                128
                                                
                                                
                                                
                                                1,909Stock-based
      compensation costs
                                                
                                                
                                                287,767
                                                
                                                
                                                
                                                306,692
                                                
                                                
                                                
                                                2,379,578Stock-based
      research and development costs
                                                
                                                
                                                81,640
                                                
                                                
                                                
                                                116,835
                                                
                                                
                                                
                                                478,470Changes
      in operating assets and liabilities:(Increase)
      decrease in -Advances
      on research and development contract services
                                                
                                                
                                                5,000
                                                
                                                
                                                
                                                12,500
                                                
                                                
                                                
                                                —Prepaid
      expenses and other current assets
                                                
                                                
                                                (8,612
                                                )
                                                
                                                
                                                (9,835
                                                )
                                                
                                                
                                                (35,966
                                                )Increase
      (decrease) in -Accounts
      payable and accrued expenses
                                                
                                                
                                                (62,163
                                                )
                                                
                                                
                                                (4,239
                                                )
                                                
                                                
                                                21,383Liquidated
      damages payable under registration rights agreement
                                                
                                                
                                                —
                                                
                                                
                                                
                                                —
                                                
                                                
                                                
                                                74,000Research
      and development contract liabilities
                                                
                                                
                                                1,679
                                                
                                                
                                                
                                                56,500
                                                
                                                
                                                
                                                51,679Net
      cash used in operating activities
                                                
                                                
                                                (732,580
                                                )
                                                
                                                
                                                (497,000
                                                )
                                                
                                                
                                                (3,116,389
                                                )Cash
      flows from investing activities:Increase
      in money market funds
                                                
                                                
                                                (1,775,822
                                                )
                                                
                                                
                                                —
                                                
                                                
                                                
                                                (1,800,822
                                                )Purchase
      of office equipment
                                                
                                                
                                                —
                                                
                                                
                                                
                                                —
                                                
                                                
                                                
                                                (1,909
                                                )Net
      cash used in investing activities
                                                
                                                
                                                (1,775,822
                                                )
                                                
                                                
                                                —
                                                
                                                
                                                
                                                (1,802,731
                                                )Cash
      flows from financing activities:Proceeds
      from sale of common stock to consulting firm
                                                
                                                
                                                —
                                                
                                                
                                                
                                                —
                                                
                                                
                                                
                                                250Proceeds
      from sale of common stock to founder
                                                
                                                
                                                —
                                                
                                                
                                                
                                                —
                                                
                                                
                                                
                                                1,500Proceeds
      from issuance of notes payable to consultant
                                                
                                                
                                                —
                                                
                                                
                                                
                                                100,000
                                                
                                                
                                                
                                                200,000Repayment
      of notes payable to consultant
                                                
                                                
                                                —
                                                
                                                
                                                
                                                (100,000
                                                )
                                                
                                                
                                                (200,000
                                                )Cash
      acquired in reverse merger transaction
                                                
                                                
                                                —
                                                
                                                
                                                
                                                —
                                                
                                                
                                                
                                                62,500Gross
      proceeds from sale of securities
                                                
                                                
                                                1,087,500
                                                
                                                
                                                
                                                710,000
                                                
                                                
                                                
                                                5,331,389Payment
      of private placement offering costs
                                                
                                                
                                                —
                                                
                                                
                                                
                                                (112,950
                                                )
                                                
                                                
                                                (446,147
                                                )Advances
      received from stockholder
                                                
                                                
                                                —
                                                
                                                
                                                
                                                —
                                                
                                                
                                                
                                                92,717Net
      cash provided by financing activities
                                                
                                                
                                                1,087,500
                                                
                                                
                                                
                                                597,050
                                                
                                                
                                                
                                                5,042,209Cash:Net
      increase (decrease)
                                                
                                                
                                                (1,420,902
                                                )
                                                
                                                
                                                100,050
                                                
                                                
                                                
                                                123,089Balance
      at beginning of period
                                                
                                                
                                                1,543,991
                                                
                                                
                                                
                                                10,381
                                                
                                                
                                                
                                                —Balance
      at end of period
                                                
                                                $
                                                123,089
                                                
                                                
                                                $
                                                110,431
                                                
                                                
                                                $
                                                123,089Supplemental
      disclosures of cash flow information:Cash
      paid for -Interest
                                                
                                                $
                                                —
                                                
                                                
                                                $
                                                851
                                                
                                                
                                                $
                                                2,465Income
      taxes
                                                
                                                $
                                                —
                                                
                                                
                                                $
                                                —
                                                
                                                
                                                $
                                                —Non-cash
      financing activities:Decrease
      in advances under equity financing
                                                
                                                $
                                                1,200,000
                                                
                                                
                                                $
                                                —
                                                
                                                
                                                $
                                                1,200,000





See
accompanying notes to condensed consolidated financial statements.




7




LIXTE
BIOTECHNOLOGY HOLDINGS, INC. AND SUBSIDIARY


(a
development stage company)





NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)




Three
Months and Nine Months Ended September 30, 2010 and 2009, and


Period
from August 9, 2005 (Inception) to September 30, 2010 (Cumulative)




1.
Basis of Presentation




The
condensed consolidated financial statements of Lixte Biotechnology Holdings,
Inc. and its wholly-owned subsidiary, Lixte Biotechnology, Inc. (the “Company”)
at September 30, 2010, for the three months and nine months ended September 30,
2010 and 2009, and for the period from August 9, 2005 (inception) to September
30, 2010 (cumulative), are unaudited. In the opinion of management, all
adjustments (including normal recurring adjustments) have been made that are
necessary to present fairly the financial position of the Company as of
September 30, 2010, the results of its operations for the three months and nine
months ended September 30, 2010 and 2009, and for the period from August 9, 2005
(inception) to September 30, 2010 (cumulative), and its cash flows for the nine
months ended September 30, 2010 and 2009, and for the period from August 9, 2005
(inception) to September 30, 2010 (cumulative). Operating results for the
interim periods presented are not necessarily indicative of the results to be
expected for a full fiscal year. The condensed balance sheet at December 31,
2009 has been derived from the audited financial statements.




The
statements and related notes have been prepared pursuant to the rules and
regulations of the Securities and Exchange Commission (the “SEC”). Accordingly,
certain information and footnote disclosures normally included in financial
statements prepared in accordance with generally accepted accounting principles
have been omitted pursuant to such rules and regulations. These financial
statements should be read in conjunction with the financial statements and other
information included in the Company’s Annual Report on Form 10-K for the fiscal
year ended December 31, 2009, as filed with the SEC.





2. 
Organization and Business Operations





Organization





On June
30, 2006, Lixte Biotechnology, Inc., a privately-held Delaware corporation
(“Lixte”) incorporated on August 9, 2005, completed a reverse merger transaction
with SRKP 7, Inc. (“SRKP”), a non-trading public shell company, whereby Lixte
became a wholly-owned subsidiary of SRKP. On December 7, 2006, SRKP amended its
Certificate of Incorporation to change its name to Lixte Biotechnology Holdings,
Inc. (“Holdings”).  Unless the context indicates otherwise, Lixte and
Holdings are hereinafter referred to as the “Company”.





For
financial reporting purposes, Lixte was considered the accounting acquirer in
the merger and the merger was accounted for as a reverse merger. Accordingly,
the historical financial statements presented herein are those of Lixte. The
stockholders’ equity section of SRKP has been retroactively restated for all
periods presented to reflect the accounting effect of the reverse merger
transaction. All costs associated with the reverse merger transaction were
expensed as incurred.





The
Company is considered a “development stage company” under current accounting
standards, as it has not yet commenced any revenue-generating operations, does
not have any cash flows from operations, and is dependent on debt and equity
funding to finance its operations.





The
Company’s common stock was listed for trading on the OTC Bulletin Board
commencing September 24, 2007 under the symbol “LIXT”.





Operating
Plans





The
Company’s original focus was the development of new treatments for the most
common and most aggressive type of brain cancer of adults, glioblastoma
multiforme (“GBM”), and the most common cancer of children, neuroblastoma. The
Company has expanded the scope of its anti-cancer investigational activities to
include the most common brain tumor of children, medulloblastoma, and also to
several other types of more common cancers. This expansion of activity is based
on documentation that each of two distinct types of drugs being developed by the
Company has activity against cell lines of breast, colon, lung, prostate,
pancreas, ovary, stomach and liver cancer, as well as against the major types of
leukemias. LB-100 has now been shown to have activity in animal models of brain
tumors of adults and children, and also against melanomas and sarcomas. 
Studies in animal models of human melanoma, lymphoma, sarcoma, brain tumors, and
the rare neuroendocrine cancer, pheochromocytoma, have demonstrated marked
potentiation by LB-100 of the anti-tumor activity of the widely used standard
chemotherapeutic drugs. These studies confirm that the LB-100 compounds,
combined with any of several “standard anti-cancer drugs”, have broad activity,
affecting many different cell types of cancer. This is unusual and important
because these compounds may be useful for treatment of cancer in
general.




8




The
research on brain tumors is proceeding in collaboration with the National
Institute of Neurological Disorders and Stroke (“NINDS”) of the National
Institutes of Health (“NIH”) under a Cooperative Research and Development
Agreement (“CRADA”) entered into on March 22, 2006, as amended. The research at
NINDS continues to be led by Dr. Zhengping Zhuang, an internationally recognized
investigator in the molecular pathology of cancer. Dr. Zhuang is aided by two
senior research technicians supported by the Company as part of the CRADA. The
goal of the CRADA is to develop more effective drugs for the treatment of GBM
through the processes required to gain Food and Drug Administration (“FDA”)
approval for clinical trials. The Company has entered into an amendment to the
CRADA to extend its term from September 30, 2009 through September 30,
2011.





During
2009, the Company signed material transfer agreements with academic
investigators at major cancer centers in the United States, as well as with one
investigator in China with a unique animal model of a sarcoma, to expand
molecular and applied studies of the anti-cancer activity of the Company’s
compounds. The Company retained the right to all discoveries made in these
studies.





The
Company’s longer-term goal is to secure one or more strategic partnerships with
pharmaceutical companies with major programs in cancer, anti-fungal treatments,
and/or neuroprotective measures. The Company’s immediate focus has shifted to
obtaining approval from the FDA to carry a lead compound of the LB-100 series
into clinical trial. The Company believes the potent activity of these drugs in
combination with standard non-specific chemotherapeutic drugs against a diverse
array of common and uncommon cancers of adults and children merits bringing this
treatment to patients as rapidly as reasonably possible. In addition, the
demonstration of clinical benefit would be important to potential investors and
to large pharmaceutical companies looking to add an entirely new approach to
their anti-cancer drug pipelines.





The
significant diversity of the potential therapeutic value of the Company’s
compounds stems from the fact that these agents modify critical pathways in
cancer cells and in microorganisms such as fungi and appear to ameliorate
pathologic processes that lead to brain injury caused by trauma or toxins or
through as yet unknown mechanisms that underlie the major chronic neurologic
diseases, including Alzheimer’s Disease, Parkinson’s Disease, and Amyotrophic
Lateral Sclerosis (ALS, or Lou Gehrig’s Disease).  Studies of the potential
neuroprotective effects of homologs of each class of the Company’s compounds are
continuing under a contract with Southern Research Institute, Birmingham,
Alabama. However, the majority of the Company’s resources will be directed to
the clinical study of LB-100 for cancer therapy.





Going
Concern





The
Company’s consolidated financial statements have been presented on the basis
that it is a going concern, which contemplates the realization of assets and
satisfaction of liabilities in the normal course of business. The Company is in
the development stage and has not generated any revenues from operations to
date, and does not expect to do so in the foreseeable future.  The Company
has experienced recurring operating losses and negative operating cash flows
since inception, and has financed its working capital requirements through the
recurring sale of its equity securities.  As a result, the Company’s
independent registered public accounting firm, in its report on the Company’s
2009 consolidated financial statements, has raised substantial doubt about the
Company’s ability to continue as a going concern.





The
Company’s ability to continue as a going concern is dependent upon its ability
to develop additional sources of capital and to ultimately achieve sustainable
revenues and profitable operations. The Company’s consolidated financial
statements do not include any adjustments that might result from the outcome of
these uncertainties.





At
September 30, 2010, the Company had not yet commenced any revenue-generating
operations. All activity through September 30, 2010 has been related to the
Company’s formation, capital raising efforts and research and development
activities. As such, the Company has yet to generate any cash flows from
operations, and is dependent on debt and equity funding from both related and
unrelated parties to finance its operations. Prior to June 30, 2006, the
Company’s cash requirements were funded by advances from the Company’s founder
aggregating $92,717.





Because
the Company is currently engaged in research at an early stage, it will likely
take a significant amount of time to develop any product or intellectual
property capable of generating revenues. As such, the Company’s business is
unlikely to generate any sustainable revenues in the next several years, and may
never do so. Even if the Company is able to generate revenues in the future
through licensing its technologies or through product sales, there can be no
assurance that the Company will be able to generate a profit.




9




The
Company’s activities for the remainder of 2010 will consist of continuing drug
discovery and development efforts. The Company’s primary goal is to take the
Company’s LB-100 compound through a Phase I clinical trial by December 31, 2011.
The Company believes that its current resources are adequate to fund operations
through 2011, at a level that will allow the continuation of the Company’s two
drug development programs currently in process and completion of the initial
Phase I trial of LB-100, if no unexpected delays occur in obtaining FDA
approval.





The
amount and timing of future cash requirements will depend on the pace of these
programs, particularly the completion of the Phase I trial of LB-100. After
completion of the Phase I trial, the next step will be to determine the
anti-cancer activity against a particular type of human cancer in Phase II
trials. To carry out Phase II trials, the Company anticipates that it will be
necessary to raise additional funds in late 2011 from a combination of debt or
equity financings, and/or the sale, licensing or joint venturing of its
intellectual properties. Market conditions present uncertainty as to the
Company’s ability to secure additional funds, as well as its ability to reach
profitability. There can be no assurances that the Company will be able to
secure additional financing, or obtain favorable terms on such financing if it
is available, or as to the Company’s ability to achieve positive earnings and
cash flows from operations. Continued negative cash flows and lack of liquidity
create significant uncertainty about the Company’s ability to fully implement
its operating plan beyond December 2011, as a result of which the Company may
have to reduce the scope of its planned operations. If cash resources are
insufficient to satisfy the Company’s liquidity requirements, the Company would
be required to scale back or discontinue its technology and product development
programs, or obtain funds, if available, through strategic alliances that may
require the Company to relinquish rights to certain of its technologies
products, or to discontinue its operations entirely.





3. 
Summary of Significant Accounting Policies





Principles
of Consolidation




The
accompanying condensed consolidated financial statements include the financial
statements of Holdings and its wholly-owned subsidiary, Lixte. All intercompany
balances and transactions have been eliminated in consolidation.





Cash
Concentrations




The
Company’s cash balances may periodically exceed federally insured limits. The
Company has not experienced a loss in such accounts to date. The Company
maintains its accounts with financial institutions with high credit
ratings.





Research
and Development





Research
and development costs are expensed as incurred.  Research and development
expenses consist primarily of fees paid to consultants and outside service
providers, patent fees and costs, and other expenses relating to the
acquisition, design, development and testing of the Company's treatments and
product candidates.





Amounts
due, pursuant to contractual commitments, on research and development contracts
with third parties are recorded as a liability, with the related amount of such
contracts recorded as advances on research and development contract services on
the Company’s balance sheet. Such advances on research and development contract
services are expensed over their life on the straight-line basis, unless the
achievement of milestones, the completion of contracted work, or other
information indicates that a different expensing schedule is more
appropriate.  The Company reviews the status of its research and
development contracts on a quarterly basis.





The funds
paid to NINDS of the NIH, pursuant to the CRADA effective March 22, 2006, as
amended, represented an advance on research and development costs and therefore
had future economic benefit. Accordingly, such costs have been charged to
expense when they are actually expended by the provider, which is, effectively,
as they perform the research activities that they were contractually committed
to provide. Absent information that would indicate that a different expensing
schedule was more appropriate (such as, for example, from the achievement of
performance milestones or the completion of contract work), such advances have
been expensed over the contractual service term on a straight-line basis, which,
in management’s opinion, reflects a reasonable estimate of when the underlying
research and development costs were being incurred.





Patent
Costs





Due to
the significant uncertainty associated with the successful development of one or
more commercially viable products based on the Company's research efforts and
any related patent applications, all patent costs, including patent-related
legal and filing fees, are expensed as incurred. Patent costs were $22,806 and
$107,999 for the three months ended September 30, 2010 and 2009, respectively,
$193,586 and $154,506 for the nine months ended September 30, 2010 and 2009,
respectively, and $718,735 for the period from August 9, 2005 (inception) to
September 30, 2010 (cumulative). Patent costs are included in research and
development costs in the Company's consolidated statements of
operations.




10




Income
Taxes





The
Company accounts for income taxes under an asset and liability approach for
financial accounting and reporting for income taxes. Accordingly, the Company
recognizes deferred tax assets and liabilities for the expected impact of
differences between the financial statements and the tax basis of assets and
liabilities.





The
Company has elected to deduct research and development costs on a current basis
for federal income tax purposes.  Start-up and organization costs are being
deferred until the Company commences revenue-generating operations, at which
time such costs will be written off over a 180-month period.





The
Company records a valuation allowance to reduce its deferred tax assets to the
amount that is more likely than not to be realized. In the event the Company was
to determine that it would be able to realize its deferred tax assets in the
future in excess of its recorded amount, an adjustment to the deferred tax
assets would be credited to operations in the period such determination was
made. Likewise, should the Company determine that it would not be able to
realize all or part of its deferred tax assets in the future, an adjustment to
the deferred tax assets would be charged to operations in the period such
determination was made.





For
federal income tax purposes, net operating losses can be carried forward for a
period of 20 years until they are either utilized or until they
expire.





On
January 1, 2007, the Company adopted new accounting rules which address the
determination of whether tax benefits claimed or expected to be claimed on a tax
return should be recorded in the financial statements.  The Company may
recognize the tax benefit from an uncertain tax position only if it is more
likely than not that the tax position will be sustained on examination by the
taxing authorities, based on the technical merits of the position. The tax
benefits recognized in the financial statements from such a position are
measured based on the largest benefit that has a greater than fifty percent
likelihood of being realized upon ultimate settlement. The new accounting rules
also provide guidance on de-recognition, classification, interest and penalties
on income taxes, accounting in interim periods and requires increased
disclosures.  The adoption of the new accounting rules did not have a
material effect on the Company’s financial statements. As of September 30, 2010,
no liability for unrecognized tax benefits was required to be
recorded.





The
Company files income tax returns in the U.S. federal jurisdiction and is subject
to income tax examinations by federal tax authorities for the year 2007 and
thereafter.  The Company’s policy is to record interest and penalties on
uncertain tax provisions as income tax expense. As of September 30, 2010, the
Company has no accrued interest or penalties related to uncertain tax
positions.




Stock-Based
Compensation




The
Company periodically issues stock options and warrants to officers, directors
and consultants for services rendered.  Options vest and expire according
to terms established at the grant date.





The
Company accounts for share-based payments to officers and directors by measuring
the cost of services received in exchange for equity awards based on the grant
date fair value of the awards, with the cost recognized as compensation expense
in the Company’s financial statements over the vesting period of the
awards.





The
Company accounts for share-based payments to consultants by determining the
value of the stock compensation based upon the measurement date at either (a)
the date at which a performance commitment is reached or (b) at the date at
which the necessary performance to earn the equity instruments is
complete.





Options
granted to Scientific Advisory Board committee members and outside consultants
are revalued each reporting period to determine the amount to be recorded as an
expense in the respective period. As the options vest, they are valued on each
vesting date and an adjustment is recorded for the difference between the value
already recorded and the then current value on the date of vesting.





Earnings
Per Share





The
Company’s computation of earnings per share (“EPS”) includes basic and diluted
EPS.  Basic EPS is measured as the income (loss) available to common
shareholders divided by the weighted average common shares outstanding for the
period.  Diluted EPS is similar to basic EPS but presents the dilutive
effect on a per share basis of potential common shares (e.g., warrants and
options) as if they had been converted at the beginning of the periods
presented, or issuance date, if later.  Potential common shares that have
an anti-dilutive effect (i.e., those that increase income per share or decrease
loss per share) are excluded from the calculation of diluted EPS.




11


Loss per
common share is computed by dividing net loss by the weighted average number of
shares of common stock outstanding during the respective periods. Basic and
diluted loss per common share is the same for all periods presented because all
warrants and stock options outstanding are anti-dilutive.





At
September 30, 2010 and 2009, the Company excluded the outstanding securities
summarized below, which entitle the holders thereof to acquire shares of common
stock, from its calculation of earnings per share, as their effect would have
been anti-dilutive.





September
      30,2010
                            
                            
                            2009Warrants
                            
                            
                            13,607,426
                            
                            
                            
                            2,457,426Stock
      options
                            
                            
                            3,540,000
                            
                            
                            
                            2,540,000Total
                            
                            
                            17,147,426
                            
                            
                            
                            4,997,426





Fair
Value of Financial Instruments





The
carrying amounts of cash, money market funds, advances on research and
development contract services, prepaid expenses and other current assets,
accounts payable and accrued expenses, research and development contract
liabilities, liquidated damages payable under registration rights agreement and
due to stockholder approximate their respective fair values due to the
short-term nature of these items.





Use
of Estimates





The
preparation of financial statements in conformity with accounting principles
generally accepted in the United States of America requires management to make
estimates and assumptions that affect the reported amounts of assets and
liabilities at the date of the financial statements and the reported amounts of
expenses during the reporting period. Actual results could differ from those
estimates.





Recent
Accounting Pronouncements





In April
2010, the Financial Accounting Standards Board (“FASB”) issued new accounting
guidance in applying the milestone method of revenue recognition to research or
development arrangements. Under this guidance, management may recognize revenue
contingent upon the achievement of a milestone in its entirety, in the period in
which the milestone is achieved, only if the milestone meets all of the criteria
within the guidance to be considered substantive. The new guidance is effective
on a prospective basis for research and development milestones achieved in
fiscal years beginning on or after June 15, 2010. Early adoption is permitted;
however, adoption of this guidance as of a date other than January 1, 2011 would
require the Company to apply this guidance retrospectively effective as of
January 1, 2010, and would require disclosure of the effect of this guidance as
applied to all previously reported interim periods in the fiscal year of
adoption. As the Company plans to implement this guidance prospectively, the
effect of this guidance will be limited to future transactions. The Company does
not expect that adoption of this guidance will have any impact on its financial
position or results of operations, as the Company does not have or currently
expect to have any research and development arrangements which will be accounted
for under the milestone method.





In
January 2010, the FASB issued new accounting guidance which requires new
disclosures regarding transfers in and out of Level 1 and Level 2 fair value
measurements, as well as requiring presentation on a gross basis of information
about purchases, sales, issuances and settlements in Level 3 fair value
measurements. The new guidance also clarifies existing disclosures regarding
level of disaggregation, inputs and valuation techniques. The new guidance is
effective for interim and annual reporting periods beginning after December 15,
2009.  Disclosures about purchases, sales, issuances and settlements in the
roll forward of activity in Level 3 fair value measurements are effective for
fiscal years beginning after December 15, 2010. As this guidance only requires
additional disclosure, the Company does not expect that adoption of this
guidance will have any impact on its financial position or results of
operations.




In April
2010, FASB issued new accounting guidance which addresses the classification of
a share-based payment award with an exercise price denominated in the currency
of a market in which the underlying equity security trades.  The new
guidance clarifies that a share-based payment award with an exercise price
denominated in the currency of a market in which a substantial portion of the
entity’s equity securities trades shall not be considered to contain a market,
performance, or service condition.   Therefore, such an award is
not to be classified as a liability if it otherwise qualifies as equity
classification.  The new guidance is effective for fiscal years, and
interim periods within those fiscal years, beginning on or after December 15,
2010.  The guidance will be applied by recording a cumulative-effect
adjustment to the opening balance of retained earnings for all outstanding
awards as of the beginning of the fiscal year in which the guidance is initially
applied.  The Company does not expect that the adoption of this
guidance will have any impact on its results of operations or financial
position.




12




Management
does not believe that any other recently issued, but not yet effective,
authoritative guidance, if currently adopted, would have a material impact on
the Company's financial statement presentation or disclosures.





4.  Share
Exchange Agreement and Private Placement





Share
Exchange Agreement





On June
30, 2006, pursuant to a Share Exchange Agreement dated as of June 8, 2006 (the
“Share Exchange Agreement”) by and among Holdings, Dr. John S. Kovach (“Seller”)
and Lixte, Holdings issued 19,021,786 shares of its common stock in exchange for
all of the issued and outstanding shares of Lixte (the “Exchange”). Previously,
on October 3, 2005, Lixte had issued 1,500 shares of its no par value common
stock to its founder for $1,500, which constituted all of the issued and
outstanding shares of Lixte prior to the Exchange. As a result of the Exchange,
Lixte became a wholly-owned subsidiary of Holdings.





Pursuant
to the Exchange, Holdings issued to the Seller 19,021,786 shares of its common
stock. Holdings had a total of 25,000,832 shares of common stock issued and
outstanding after giving effect to the Exchange and the 1,973,869 shares of
common stock issued in the initial closing of the private
placement.





As a
result of the Exchange and the shares of common stock issued in the initial
closing of the private placement, on June 30, 2006, the stockholders of the
Company immediately prior to the Exchange owned 4,005,177 shares of common
stock, equivalent to approximately 16% of the issued and outstanding shares of
the Company’s common stock, and the former stockholder of Lixte acquired control
of the Company.





The Share
Exchange Agreement was determined through arms-length negotiations between
Holdings, the Seller and Lixte. In connection with the Exchange, the Company
paid WestPark Capital, Inc. an aggregate cash fee of $50,000.





Private
Placements





On June
30, 2006, concurrently with the closing of the Exchange, the Company sold an
aggregate of 1,973,869 shares of its common stock to accredited investors in an
initial closing of a private placement at a per share price of $0.333, resulting
in aggregate gross proceeds to the Company of $657,299. The Company paid to
WestPark Capital, Inc., as placement agent, a commission of 10% and a
non-accountable fee of 4% of the gross proceeds of the private placement and
issued five-year warrants to purchase common stock equal to (a) 10% of the
number of shares sold in the private placement exercisable at $0.333 per share
and (b) an additional 2% of the number of shares sold in the private placement
also exercisable at $0.333 per share. A total of 236,864 warrants were issued.
Net cash proceeds to the Company, after the deduction of all private placement
offering costs and expenses, were $522,939.





On July
27, 2006, the Company sold an aggregate of 1,581,351 shares of its common stock
to accredited investors in a second closing of the private placement at a per
share price of $0.333 resulting in aggregate gross proceeds to the Company of
$526,590. The Company paid to WestPark Capital, Inc., as placement agent, a
commission of 10% and a non-accountable fee of 4% of the gross proceeds of the
private placement and issued five-year warrants to purchase common stock equal
to (a) 10% of the number of shares sold in the private placement exercisable at
$0.333 per share and (b) an additional 2% of the number of shares sold in the
private placement also exercisable at $0.333 per share. A total of 189,762
warrants were issued. Net cash proceeds to the Company were
$446,433.





In
conjunction with the private placement of common stock, the Company issued a
total of 426,626 five-year warrants to WestPark Capital, Inc. exercisable at the
per share price of the common stock sold in the private placement ($0.333 per
share). The warrants issued to WestPark Capital, Inc. do not contain any price
anti-dilution provisions. However, such warrants contain cashless exercise
provisions and demand registration rights, but the warrant holder has agreed to
waive any claims to monetary damages or financial penalties for any failure by
the Company to comply with such registration requirements. Based on the
foregoing, the warrants were accounted for as equity and were not accounted for
separately from the common stock and additional paid-in capital
accounts.  The warrants had no accounting impact on the Company’s
consolidated financial statements.




13




As part
of the Company’s private placement of its securities completed on July 27, 2006,
the Company entered into a registration rights agreement with the purchasers,
whereby the Company agreed to register the shares of common stock sold in the
private placement, and to maintain the effectiveness of such registration
statement, subject to certain conditions. The agreement required the Company to
file a registration statement within 45 days of the closing of the private
placement and to have the registration statement declared effective within 120
days of the closing of the private placement. On September 8, 2006, the Company
filed a registration statement on Form SB-2 to register 3,555,220 shares of the
common stock sold in the private placement. Since the registration statement was
not declared effective by the Securities and Exchange Commission within 120 days
of the closing of the private placement, the Company was required to pay each
investor prorated liquidated damages equal to 1.0% of the amount raised per
month, payable monthly in cash.





On the
date of the closing of the private placement, the Company believed it would meet
the deadlines under the registration rights agreement with respect to filing a
registration statement and having it declared effective by the Securities and
Exchange Commission. As a result, the Company did not record any liabilities
associated with the registration rights agreement at June 30, 2006. At December
31, 2006, the Company determined that the registration statement covering the
shares sold in the private placement would not be declared effective within the
requisite time frame and therefore accrued six months liquidated damages under
the registration rights agreement aggregating approximately $74,000, which has
been presented as a current liability for all periods presented. The Company’s
registration statement on Form SB-2 was declared effective by the Securities and
Exchange Commission on May 14, 2007. At September 30, 2010, the registration
penalty to the investors had not been paid.





On
December 12, 2007, the Company sold an aggregate of 999,995 shares of its common
stock to accredited investors in a second private placement at a per share price
of $0.65, resulting in aggregate gross proceeds to the Company of $650,000. The
Company paid to WestPark Capital, Inc., as placement agent, a commission of 10%
and a non-accountable fee of 4% of the gross proceeds of the private placement
and issued five-year warrants to purchase common stock equal to (a) 10% of the
number of shares sold in the private placement exercisable at $0.65 per share
and (b) an additional 2% of the number of shares sold in the private placement
also exercisable at $0.65 per share. Net cash proceeds to the Company were
$531,320.




In
conjunction with the second private placement of common stock, the Company
issued a total of 120,000 five-year warrants to WestPark Capital, Inc.
exercisable at the per share price of the common stock sold in the private
placement ($0.65 per share). The warrants issued to WestPark Capital, Inc. do
not contain any price anti-dilution provisions. However, such warrants contain
cashless exercise provisions and demand registration rights, but the warrant
holder has agreed to waive any claims to monetary damages or financial penalties
for any failure by the Company to comply with such registration requirements.
Based on the foregoing, the warrants were accounted for as equity and were not
accounted for separately from the common stock and additional paid-in capital
accounts.  The warrants had no accounting impact on the Company’s
consolidated financial statements.





As part
of the Company’s second private placement of its securities completed on
December 12, 2007, the Company entered into a registration rights agreement with
the purchasers, whereby the Company agreed to register the shares of common
stock sold in the second private placement at its sole cost and expense. The
registration rights agreement terminates at such time as the common shares may
be sold in market transactions without regard to any volume limitations. The
registration rights agreement requires the Company to file a registration
statement within 75 days of receipt of written demand from holders who represent
at least 50% of the common shares issued pursuant to the second private
placement, provided that no demand shall be made for less than 500,000 shares,
and to use its best efforts to cause such registration statement to become and
remain effective for the requisite period. The registration rights agreement
also provides for unlimited piggyback registration rights. The registration
rights agreement does not provide for any penalties in the event that the
Company is unable to comply with its terms.





During
the year ended December 31, 2009, the Company completed three closings of the
third private placement of common stock units, consisting of a total of
1,420,000 shares of common stock and 1,420,000 warrants to acquire common stock,
as follows:





On
February 10, 2009, the Company sold an aggregate of 658,000 common stock units
to accredited investors in a first closing of a third private placement at a per
unit price of $0.50, resulting in aggregate gross proceeds to the Company of
$329,000. Net cash proceeds to the Company were $269,790.





On March
2, 2009, the Company sold an aggregate of 262,000 common stock units to
accredited investors in a second closing of the third private placement at a per
unit price of $0.50, resulting in aggregate gross proceeds to the Company of
$131,000. Net cash proceeds to the Company were $112,460.





On April
6, 2009, the Company sold an aggregate of 500,000 common stock units to
accredited investors in a third closing of the third private placement at a per
unit price of $0.50, resulting in aggregate gross proceeds to the Company of
$250,000. Net cash proceeds to the Company were $214,800.




14




Each unit
sold in the third private placement consisted of one share of the Company’s
common stock and a five-year warrant to purchase an additional share of the
Company’s common stock on a cashless exercise basis at an exercise price of
$0.50 per common share. The Company paid to WestPark Capital, Inc., as placement
agent, a commission of 10% and a non-accountable fee of 4% of the gross proceeds
of the third private placement and issued five-year warrants to purchase common
stock equal to (a) 10% of the number of shares sold in the third private
placement exercisable at $0.50 per share and 10% of the number of shares
issuable upon exercise of warrants issued in the third private placement
exercisable at $0.50 per share; and (b) an additional 2% of the number of shares
sold in the third private placement also exercisable at $0.50 per share and 2%
of the number of shares issuable upon exercise of the warrants issued in the
third private placement exercisable at $0.50 per share.





In
conjunction with the closings of the third private placement of common stock
units during the year ended December 31, 2009, the Company issued a total of
340,800 five-year warrants to WestPark Capital, Inc., which are exercisable at
the per unit price of the common stock units sold in the third private placement
($0.50 per unit). Included in the 340,800 warrants issued to WestPark Capital,
Inc. are 170,400 warrants which are only exercisable with respect to common
shares that are acquired by investors upon their exercise of the warrants
acquired as part of the units sold in the third private placement. The warrants
issued to WestPark Capital, Inc. do not contain any price anti-dilution
provisions. However, such warrants contain cashless exercise provisions and
demand registration rights, but the warrant holder has agreed to waive any
claims to monetary damages or financial penalties for any failure by the Company
to comply with such registration requirements. Based on the foregoing, the
warrants were accounted for as equity and were not accounted for separately from
the common stock and additional paid-in capital accounts.  The
warrants had no accounting impact on the Company’s consolidated financial
statements.




At the
request of the holders, the Company has agreed to include any shares sold in the
third private placement and any shares issuable upon exercise of the related
warrants to be included in any registration statement filed with the Securities
and Exchange Commission permitting the resale of such shares, subject to
customary cutbacks, at the Company’s sole cost and expense.





Effective
November 6, 2009, the Company sold 1,000,000 common stock units to an accredited
investor in a fourth private placement at a per unit price of $0.50, resulting
in proceeds to the Company of $500,000. There were no commissions paid with
respect to the fourth private placement. The closing price of the Company’s
common stock on November 6, 2009 was $0.50 per share.





Each unit
sold in the fourth private placement consisted of one share of the Company’s
common stock, one three-year warrant to purchase an additional share of the
Company’s common stock at an exercise price of $0.50 per share, and one
three-year warrant to purchase an additional share of the Company’s common stock
at an exercise price of $0.75 per share. The warrants do not have any reset
provisions.





At the
request of the holder, the Company has agreed to include the shares sold in the
fourth private placement and any shares issuable upon exercise of the related
warrants in any registration statement filed by the Company with the Securities
and Exchange Commission permitting the resale of such securities, subject to
customary cutbacks. The units sold were not registered under the Securities Act
of 1933, as amended (the “Act”), in reliance upon the exemption from
registration contained in Section 4(2) of the Act and Regulation D promulgated
thereunder. Based on the foregoing, the warrants were accounted for as equity
and were not accounted for separately from the common stock and additional
paid-in capital accounts.  The warrants had no accounting impact on
the Company’s consolidated financial statements.





Effective
January 20, 2010, the Company raised $1,787,500 in a fifth private placement of
units sold to certain of its existing stockholders or their designees, all of
whom were accredited investors, consisting of an aggregate of 3,575,000 units at
a purchase price of $0.50 per unit.  Each unit consisted of one share
of common stock, one three-year warrant to purchase a share of common stock at
an exercise price of $0.50 per share, and one three-year warrant to purchase a
share of common stock at an exercise price of $0.75 per share.  The
warrants do not have any reset provisions.  The closing price of the
Company’s common stock on January 20, 2010 was $0.49 per share.  There
were no commissions paid with respect to the private placement.  Upon
request by the holder, the Company has agreed to include the shares issued and
those shares issuable upon exercise of the warrants in any registration
statement filed by the Company with the Securities and Exchange Commission
permitting the resale of such securities, subject to customary cutbacks. The
units sold were not registered under the Act, in reliance upon the exemption
from registration contained in Section 4(2) of the Act and Regulation D
promulgated thereunder. The Company accounted for the issuance of the units as a
capital transaction. As of December 31, 2009, $1,200,000 had been advanced to
the Company under this private placement, with the balance of $587,500 being
received by the Company in January 2010.





Effective
February 22, 2010, the Company raised $500,000 through the sale to an accredited
investor of 1,000,000 units at a purchase price of $0.50 per
unit.  Each unit consisted of one share of common stock, one
three-year warrant to purchase a share of common stock at an exercise price of
$0.50 per share, and one three year-year warrant to purchase a share of common
stock at an exercise price of $0.75 per share.  The warrants do not
have any reset provisions.  The closing price of the Company’s common
stock on February 22, 2010 was $0.50 per share.  There were no
commissions paid with respect to the private placement.  Upon request
by the holder, the Company has agreed to include the shares issued and those
shares issuable upon exercise of the warrants in any registration statement
filed by the Company with the Securities and Exchange Commission permitting the
resale of such securities, subject to customary cutbacks. The units sold were
not registered under the Act, in reliance upon the exemption from registration
contained in Section 4(2) of the Act and Regulation D promulgated thereunder.
The Company accounted for the issuance of the units as a capital
transaction.




15




5.  Money Market Funds — Fair
Value





Money
market funds at September 30, 2010 and December 31, 2009 consisted of an
investment in the Class A Shares of Western Asset New York Municipal Money
Market Fund with a market value of $1,800,822 and $25,000,
respectively.  The stated purpose of this money market fund is to
provide income exempt from both regular federal income tax and New York State
and New York City personal income tax from a portfolio of high quality
short-term municipal obligations selected for liquidity and stability of
principal.





The
authoritative guidance with respect to fair value established a fair value
hierarchy that prioritizes the inputs to valuation techniques used to measure
fair value into three levels, and requires that assets and liabilities carried
at fair value are classified and disclosed in one of three categories, as
presented below.  Disclosure as to transfers in and out of Levels 1
and 2, and activity in Level 3 fair value measurements, is also
required.





Level
1:  quoted prices (unadjusted) in active markets for an identical asset or
liability that the Company has the ability to access as of the measurement
date.  Financial assets and liabilities utilizing Level 1 inputs include
active-exchange traded securities and exchange-based derivatives.





Level
2:  inputs other than quoted prices included within Level 1 that are
directly observable for the asset or liability or indirectly observable through
corroboration with observable market data.  Financial assets and
liabilities utilizing Level 2 inputs include fixed income securities,
non-exchange based derivatives, mutual funds, and fair-value
hedges.





Level
3:  unobservable inputs for the asset or liability are only used when there
is little, if any, market activity for the asset or liability at the measurement
date.  Financial assets and liabilities utilizing Level 3 inputs include
infrequently-traded non-exchange-based derivatives and commingled investment
funds, and are measured using present value pricing models.





The
Company determines the level in the fair value hierarchy within which each fair
value measurement falls in its entirety, based on the lowest level input that is
significant to the fair value measurement in its entirety.  In determining
the appropriate levels, the Company performs an analysis of the assets and
liabilities at each reporting period end.





Money
market funds are the only financial instrument that is measured and recorded at
fair value on the Company’s balance sheet on a recurring basis.  The
following table presents money market funds at their level within the fair value
hierarchy at September 30, 2010 and December 31, 2009.





Total
                      
                      
                      Level 1
                      
                      
                      Level 2
                      
                      
                      Level 3September
      30, 2010:Money
      market funds
                      
                      $
                      1,800,822
                      
                      
                      $
                      1,800,822
                      
                      
                      $
                      —
                      
                      
                      $
                      —December
      31, 2009:Money
      market funds
                      
                      $
                      25,000
                      
                      
                      $
                      25,000
                      
                      
                      $
                      —
                      
                      
                      $
                      —





6.  Related
Party Transactions





Prior to
June 30, 2006, the Company’s founding stockholder and Chief Executive Officer,
Dr. John Kovach, had periodically made advances to the Company to meet operating
expenses. Such advances are non-interest-bearing and are due on demand. At
September 30, 2010 and December 31, 2009, stockholder advances totaled
$92,717.





The
Company’s office facilities have been provided without charge by Dr. Kovach.
Such costs were not material to the financial statements and, accordingly, have
not been reflected therein.





Dr.
Kovach did not receive any compensation from the Company during the three months
and nine months ended September 30, 2010 and 2009, and for the period from
August 9, 2005 (inception) through September 30, 2010 (cumulative), in view of
the Company’s development stage status and limited resources. Any future
compensation arrangements will be subject to the approval of the Board of
Directors.




16




Dr.
Kovach is involved in other business activities and may, in the future, become
involved in other business opportunities that become available. Accordingly, he
may face a conflict in selecting between the Company and his other business
interests. The Company has not yet formulated a policy for the resolution of
such potential conflicts.





7.  Notes
Payable to Consultant





On
October 3, 2008, the Company borrowed $100,000 from Gil Schwartzberg, a
consultant to the Company, pursuant to an unsecured demand promissory note with
interest at 5% per annum, to fund the Company’s short-term working capital
requirements. The note, including accrued interest of $834, was repaid on
February 7, 2009. An additional interest payment of $851 was made on April 27,
2009.





On
September 30, 2009, the Company borrowed $100,000 from Gil Schwartzberg pursuant
to an unsecured demand promissory note with interest at 5% per annum, to fund
the Company’s short-term working capital requirements. The note, including
accrued interest of $780, was repaid on November 26, 2009.





Additional
transactions between the Company and Gil Schwartzberg are described in Note
9.





8.  Common
Stock and Preferred Stock





The
Company’s Certificate of Incorporation provides for authorized capital of
110,000,000 shares, of which 100,000,000 shares consist of common stock with a
par value of $0.0001 per share and 10,000,000 shares consist of preferred stock
with a par value of $0.0001 per share.





The
Company is authorized to issue 10,000,000 shares of preferred stock with such
designations, voting and other rights and preferences as may be determined from
time to time by the Board of Directors.





9.  Stock
Options and Warrants





On June
30, 2006, effective with the closing of the Exchange, the Company granted to
Dr. Philip Palmedo, an outside director of the Company, stock options to
purchase an aggregate of 200,000 shares of common stock, exercisable for a
period of five years at $0.333 per share, with one-third of the options (66,666
shares) vesting immediately upon joining the Board and one-third vesting
annually on each of June 30, 2007 and 2008. The fair value of these options, as
calculated pursuant to the Black-Scholes option-pricing model, was determined to
be $62,000 ($0.31 per share), of which $20,666 was charged to operations on June
30, 2006, and the remaining $41,334 was charged to operations ratably from July
1, 2006 through June 30, 2008.





On June
30, 2006, effective with the closing of the Exchange, the Company also granted
to Dr. Palmedo additional stock options to purchase 190,000 shares of
common stock exercisable for a period of five years at $0.333 per share for
services rendered in developing the business plan for Lixte, all of which were
fully vested upon issuance. The fair value of these options, as calculated
pursuant to the Black-Scholes option-pricing model, was determined to be $58,900
($0.31 per share), and was charged to operations at June 30, 2006.





On June
30, 2006, effective with the closing of the Exchange, the Company granted to two
members of its Scientific Advisory Committee stock options to purchase an
aggregate of 100,000 shares of common stock exercisable for a period of five
years at $0.333 per share, with one-half of the options vesting annually on each
of June 30, 2007 and June 30, 2008. The fair value of these options, as
calculated pursuant to the Black-Scholes option-pricing model, was charged to
operations ratably from July 1, 2006 through June 30, 2008. In August 2008, one
of the members resigned from his position and waived his right to his vested
stock option to purchase 50,000 shares of common stock.




On June
30, 2006, the fair value of the aforementioned stock options was initially
calculated using the following Black-Scholes input variables:  stock
price - $0.333; exercise price - $0.333; expected life - 5 to 7 years; expected
volatility - 150%; expected dividend yield - 0%; risk-free interest rate - 5%.
On June 30, 2007, the Black-Scholes input variables utilized to determine the
fair value of the aforementioned stock options were stock price - $0.333;
exercise price - $0.333; expected life - 4 to 6 years; expected volatility -
150%; expected dividend yield - 0%; risk-free interest rate - 4.5%. On June 30,
2008, the fair value of the aforementioned stock options was calculated using
the following Black-Scholes input variables: stock price - $0.30; exercise price
- $0.333; expected life - 3 to 5 years; expected volatility - 154.5%; expected
dividend yield - 0%; risk-free interest rate - 3.28%.




17




On
February 5, 2007, the Company entered into an agreement (the “Chem-Master
Agreement”)  with Chem-Master International, Inc. (“Chem-Master”), a
company co-owned by Francis Johnson, a consultant to the Company, pursuant to
which the Company granted a five-year option to purchase 100,000 shares of the
Company’s common stock at an exercise price of $0.333 per share. The fair value
of this option, as calculated pursuant to the Black-Scholes option-pricing
model, was determined to be $31,000 ($0.31 per share) using the following
Black-Scholes input variables: stock price on date of grant - $0.333; exercise
price - $0.333; expected life - 5 years; expected volatility - 150%; expected
dividend yield - 0%; risk-free interest rate - 4.5%. The $31,000 fair value was
charged to operations as research and development costs on February 5, 2007 as
the option was fully vested and non-forfeitable on the date of issuance. The
Company has the right to terminate the Chem-Master Agreement at any time during
its term upon sixty days prior written notice. On February 5, 2009, provided
that the Chem-Master Agreement had not been terminated prior to such date, the
Company agreed to grant Chem-Master a second five-year option to purchase an
additional 100,000 shares of the Company’s common stock at an exercise price of
$0.333 per share. As of September 30, 2008, the Company determined that it was
likely that this option would be issued. Accordingly, the fair value of the
option has been reflected as a charge to operations for the period from October
1, 2008 through February 5, 2009. On February 5, 2009, the fair value of this
option, as calculated pursuant to the Black-Scholes option-pricing model, was
determined to be $60,000 ($0.60 per share), which resulted in a charge to
operations of $19,143 during the three months ended March 31, 2009. The Company
granted the second five-year option on February 5, 2009.





On
September 30, 2008, the fair value of the aforementioned stock option was
initially calculated using the following Black-Scholes input variables: stock
price - $0.50; exercise price - $0.333; expected life – 5.35 years; expected
volatility – 275.7%; expected dividend yield - 0%; risk-free interest rate –
2.48%. On February 5, 2009, the fair value of the aforementioned stock option
was calculated for the stock option revaluation purposes using the following
Black-Scholes input variables: stock price - $0.60; exercise price - $0.333;
expected life – 5 years; expected volatility – 414.1%; expected dividend yield -
0%; risk-free interest rate – 1.89%.





On
January 29, 2008, the Chem-Master Agreement was amended to extend its term to
February 15, 2014. Pursuant to the amendment, the Company issued 100,000 shares
of its restricted common stock, valued at $75,000, and granted an option to
purchase 200,000 shares of common stock. The option is exercisable for a period
of two years from the vesting date at $1.65 per share, with one-half (100,000
shares) vesting on August 1, 2009, and one-half (100,000 shares) vesting on
February 1, 2011. The fair value of this option, as calculated pursuant to the
Black-Scholes option-pricing model, was initially determined to be $96,000
($0.48 per share) using the following Black-Scholes input variables: stock price
on date of grant - $0.75; exercise price - $1.65; expected life - 5 years;
expected volatility - 120.1%; expected dividend yield - 0%; risk-free interest
rate - 3.09%.





The fair
value of the restricted common stock issued was charged to operations as
research and development costs on January 29, 2008. On September 30, 2010, the
fair value of the aforementioned stock options was determined to be $120,000
($0.60 per share) calculated using the following Black-Scholes input variables:
stock price - $0.63; exercise price - $1.65; expected life - 2.34 years;
expected volatility – 290.6%; expected dividend yield - 0%; risk-free interest
rate - 0.52%, which resulted in a charge to operations of $27,620 and $33,406
during the three months and nine months ended September 30, 2010, respectively.
On Sptember 30, 2009, the fair value of the aforementioned stock options was
determined to be $136,000 ($0.68 per share) calculated using the following
Black-Scholes input variables: stock price - $0.70; exercise price - $1.65;
expected life - 3.5 years; expected volatility – 259.1%; expected dividend yield
- 0%; risk-free interest rate - 1.91%, which resulted in a charge to operations
of $5,332 and $41,171 during the three months and nine months ended September
30, 2009..





On June
20, 2007, the Board of Directors of the Company approved the 2007 Stock
Compensation Plan (the “2007 Plan”), which provides for the granting of awards,
consisting of common stock options, stock appreciation rights, performance
shares, or restricted shares of common stock, to employees and independent
contractors, for up to 2,500,000 shares of the Company’s common stock, under
terms and condition, as determined by the Company’s Board of
Directors.





On
September 12, 2007, in conjunction with his appointment as a director of the
Company, the Company granted to Dr. Stephen Carter stock options to purchase an
aggregate of 200,000 shares of common stock under the 2007 Plan, exercisable for
a period of five years from vesting date at $0.333 per share, with one-half
(100,000 shares) vesting annually on each of September 12, 2008 and 2009. The
fair value of these options, as calculated pursuant to the Black-Scholes
option-pricing model, was determined to be $204,000 ($1.02 per share), and was
charged to operations ratably from September 12, 2007 through September 12,
2009. During the three months and nine months ended September 30, 2009, the
Company recorded a charge to operations of $20,679 and $71,260, respectively,
with respect to these options. Effective April 20, 2010, Dr. Carter resigned as
a director for personal reasons.  Consequently, pursuant to the stock
option agreement, Dr. Carter has twelve months from April 20, 2010 to exercise
his stock options to acquire 200,000 shares of the Company’s common
stock.





On
September 12, 2007, the Company entered into a consulting agreement with Gil
Schwartzberg, pursuant to which the Company granted to Mr. Schwartzberg stock
options to purchase an aggregate of 1,000,000 shares of common stock,
exercisable for a period of four years from the vesting date at $1.00 per share,
with one-half of the options (500,000 shares) vesting immediately and one-half
(500,000 shares) vesting on September 12, 2008. The fair value of these options,
as calculated pursuant to the Black-Scholes option-pricing model, was initially
determined to be $945,000 ($0.945 per share), of which $465,000 was attributed
to the fully-vested options and was thus charged to operations on September 12,
2007. The remaining unvested portion of the fair value of the options was
charged to operations ratably from September 12, 2007 through September 12,
2008. On September 12, 2008, the fair value of these options, as calculated
pursuant to the Black-Scholes option-pricing model, was determined to be
$325,000 ($0.65 per share).





18




On
October 15, 2009, the Company amended the above described consulting agreement
with Gil Schwartzberg to extend it for an additional four years and granted to
Mr. Schwartzberg stock options to purchase an additional aggregate of 1,000,000
shares of common stock, exercisable for a period of four years from the vesting
date at $1.00 per share, with one-half of the options (500,000 shares) vesting
immediately and one-half (500,000 shares) vesting on October 15, 2010. The fair
value of these options, as calculated pursuant to the Black-Scholes
option-pricing model, was determined to be $750,000 ($0.75 per share) on October
15, 2009, of which $375,000 was attributed to the fully-vested options and was
thus charged to operations on October 15, 2009. The remaining unvested portion
of the fair value of the options is being charged to operations ratably from
October 15, 2009 through October 15, 2010. On September 30, 2010, the fair value
of the aforementioned stock options was determined to be $315,000 ($0.63 per
share) calculated using the following Black-Scholes input variables: stock price
- $0.63; exercise price - $1.00; expected life - 4.04 years; expected volatility
– 290.6%; expected dividend yield - 0%; risk-free interest rate - 0.52%, which
resulted in a charge to operations of $181,890 and $250,369 during the three
months and nine months ended September 30, 2010, respectively.




On
September 12, 2007, the Company entered into a consulting agreement with Francis
Johnson, a co-owner of Chem-Master International, Inc., and granted to Professor
Johnson stock options to purchase an aggregate of 300,000 shares of common
stock, exercisable for a period of four years from the vesting date at $0.333
per share, with one-third (100,000 shares) vesting annually on each of September
12, 2008, 2009 and 2010. The fair value of these options, as calculated pursuant
to the Black-Scholes option-pricing model, was initially determined to be
$300,000 ($1.00 per share), and is being charged to operations ratably from
September 12, 2007 through September 12, 2010. On September 12, 2010, the fair
value of these options, as calculated pursuant to the Black-Scholes
option-pricing model, was determined to be $189,000 ($0.63 per share) which
resulted in a charge to operations of $35,893 and $48,233 during the three
months and nine months ended September 30, 2010.  On September 30,
2009, the fair value of these options, as calculated pursuant to the
Black-Scholes option-pricing model, was determined to be $150,000 ($0.50 per
share) which resulted in a charge to operations of $13,904 and $56,521 during
the three months and nine months ended September 30, 2009


.


On
September 12, 2007, the fair value of the aforementioned stock options was
initially calculated using the following Black-Scholes input variables: stock
price - $1.05; exercise price - $0.333 to $1.00; expected life - 4 to 6 years;
expected volatility - 150%; expected dividend yield - 0%; risk-free interest
rate - 5%. On October 15, 2009, the fair value of the aforementioned stock
options was initially calculated using the following Black-Scholes input
variables: stock price - $0.75; exercise price - $1.00; expected life - 5 years;
expected volatility – 259.1%; expected dividend yield - 0%; risk-free interest
rate – 1.91%. On September 12, 2010 and September 30, 2010, the fair value of
the aforementioned stock options was calculated for the stock option revaluation
purposes using the following Black-Scholes input variables:  stock
price - $0.63; exercise price - $0.333; expected life – 4.02 years; expected
volatility – 209.6%; expected dividend yield - 0%; risk-free interest rate -
0.52%. On September 30, 2009, the fair value of the aforementioned stock options
was calculated for the stock option revaluation purposes using the following
Black-Scholes input variables:  stock price - $0.75; exercise price -
$0.333; expected life - 4.98; expected volatility – 259.1%; expected dividend
yield - 0%; risk-free interest rate – 0.52%.





As the
Company’s common stock commenced trading on September 24, 2007, the Company was
able to utilize such trading data to generate revised volatility factors at
September 30, 2010 and 2009.




On
September 20, 2007, the Company entered into a one-year consulting agreement
(the “Mirador Agreement”) with Mirador Consulting, Inc. (“Mirador”), pursuant to
which Mirador was to provide the Company with various financial services.
Pursuant to the Mirador Agreement, the Company agreed to pay Mirador $5,000 per
month and also agreed to sell Mirador 250,000 shares of the Company’s restricted
common stock for $250 ($0.001 per share). The fair value of this transaction was
determined to be in excess of the purchase price by $262,250 ($1.049 per share),
reflecting the difference between the $0.001 purchase price and the $1.05 price
per share as quoted on the OTC Bulletin Board on the transaction date, and was
charged to operations as stock-based compensation on September 20, 2007, being
that the shares were fully vested and non-forfeitable on the date of
issuance.





On
October 7, 2008, the Company appointed Dr. Mel Sorensen to its Board of
Directors. Dr. Sorensen is a medical oncologist with extensive experience in
cancer drug development, first at the National Cancer Institute, then at Bayer
and GlaxoSmithKline, before becoming President and Chief Executive Officer of a
new cancer therapeutics company, Ascenta Therapeutics, in 2004. Dr. Sorensen was
paid an annual consulting fee of $40,000, payable in quarterly installments over
a one year period commencing October 7, 2008, to assist the Company in
identifying a strategic partner. Dr. Sorensen was also granted a stock option to
purchase 200,000 shares of the Company’s common stock, exercisable at $0.50 per
share for a period of five years from each tranche’s vesting date. The option
vests as to 25,000 shares on January 1, 2009, and a further 25,000 shares on the
first day of each subsequent calendar quarter until all of the shares are
vested. The fair value of these options, as calculated pursuant to the
Black-Scholes option-pricing model, was determined to be $100,000 ($0.50 per
share), and is being charged to operations ratably from October 7, 2008 through
October 7, 2010. During the three months ended September 30, 2010 and 2009, the
Company recorded a charge to operations of $12,603 and $12,603, respectively,
with respect to these options. During the nine months ended September 30, 2010
and 2009, the Company recorded a charge to operations of $37,398 and $37,432,
respectively, with respect to these options. On April 7, 2010, a new agreement
was established with Dr. Sorensen providing for consultation and advice over the
ensuing twelve month period regarding the preparation and strategy for obtaining
FDA approval for the clinical trial of the lead compound of the LB-100 series
for an annual fee of $25,000, payable in two installments of $12,500 each due on
April 15, 2010 and October 15, 2011.




19




On
October 7, 2008, the fair value of the aforementioned stock options was
calculated using the following Black-Scholes input variables:  stock
price - $0.50; exercise price - $0.50; expected life - 5 years; expected
volatility – 275.7%; expected dividend yield - 0%; risk-free interest rate –
2.48%.




On July
27, 2009, the Company entered into an agreement with Pro-Active Capital Group,
LLC (“Pro-Active”) to retain Pro-Active on a non-exclusive basis for a period of
twelve months to provide consulting advice to the Company to assist the Company
in obtaining research coverage, gaining web-site exposure and coverage on
financial blogs and web-sites, enhancing the Company’s visibility to the
institutional, retail brokerage and on-line trading communities, and organizing,
or assisting in organizing, investor road-shows and presentations.  In
exchange for such consulting advice, at the initiation of the agreement, the
Company agreed to issue to Pro-Active 150,000 shares of restricted common stock
and three-year warrants to purchase an aggregate of 150,000 shares of common
stock, exercisable 50,000 at $0.75 per share, 50,000 at $1.00 per share, and
50,000 at $1.25 per share. The fair value of the 150,000 shares issued was
determined to be $100,500 ($0.67 per share), reflecting the price per share of
the Company’s common stock, as quoted on the OTC Bulletin Board, on the
transaction date. The fair value of the three-year warrants, as calculated
pursuant to the Black-Scholes option-pricing model, was determined to be $97,500
($0.65 per share) using the following Black-Scholes input variables: stock price
on date of grant - $0.67; exercise price - $0.75 to $1.25; expected life - 3
years; expected volatility – 259.1%; expected dividend yield - 0%; risk-free
interest rate - 1.91%. The $198,000 aggregate fair value of the shares and
warrants issued was charged to operations as stock-based compensation on July
27, 2009, as the shares and warrants were fully vested and non-forfeitable on
the date of issuance.





Additional
information with respect to common stock warrants and stock options issued is
provided at Notes 4 and 10.




If and
when the aforementioned stock options and warrants are exercised, the Company
expects to satisfy such stock obligations through the issuance of authorized but
unissued shares of common stock.





A summary
of stock option and warrant activity, including warrants to purchase common
stock that were issued in conjunction with the Company’s private placements, is
presented in the tables below.




Number
                                                  of
                                                  Shares
                                                
                                                
                                                Weighted
                                                  Average
                                                  Exercise
                                                  Price
                                                
                                                
                                                Weighted
                                                  Average
                                                  Remaining
                                                  Contractual
                                                  Life
                                                  (in Years)Options
      and warrants outstanding at December 31, 2007
                                                
                                                
                                                2,636,626
                                                
                                                
                                                $
                                                0.600Granted
                                                
                                                
                                                500,000
                                                
                                                
                                                
                                                0.927Exercised
                                                
                                                
                                                —
                                                
                                                
                                                
                                                —Cancelled
                                                
                                                
                                                (50,000
                                                )
                                                
                                                
                                                0.333Options
      and warrants outstanding at December 31, 2008
                                                
                                                
                                                3,086,626
                                                
                                                
                                                
                                                0.658Granted
                                                
                                                
                                                4,910,800
                                                
                                                
                                                
                                                0.668Exercised
                                                
                                                
                                                —
                                                
                                                
                                                
                                                —Cancelled
                                                
                                                
                                                —
                                                
                                                
                                                
                                                —Options
      and warrants outstanding at December 31, 2009
                                                
                                                
                                                7,997,426
                                                
                                                
                                                $
                                                0.664Granted
                                                
                                                
                                                9,150,000
                                                
                                                
                                                
                                                0.625Exercised
                                                
                                                
                                                —
                                                
                                                
                                                
                                                —Cancelled
                                                
                                                
                                                —
                                                
                                                
                                                
                                                —Options
      and warrants outstanding at September 30, 2010
                                                
                                                
                                                17,147,426
                                                
                                                
                                                $
                                                0.643
                                                
                                                
                                                
                                                2.39Options
      and warrants exercisable at December 31, 2009
                                                
                                                
                                                7,027,026
                                                
                                                
                                                $
                                                0.637Options
      and warrants exercisable at September 30, 2010
                                                
                                                
                                                16,352,026
                                                
                                                
                                                $
                                                0.628
                                                
                                                
                                                
                                                2.32




20




The
intrinsic value of exercisable but unexercised in-the-money stock options and
warrants at September 30, 2010 was $1,419,540, based on a fair market value of
$0.63 per share on September 30, 2010. The intrinsic value of exercisable but
unexercised in-the-money stock options and warrants at December 31, 2009 was
$230,260, based on a fair market value of $0.49 per share on December 31,
2009.





Total
deferred compensation expense for the outstanding value of unvested stock
options was approximately $26,485 at September 30, 2010, which is being
recognized subsequent to September 30, 2010 over a weighted-average period of
2.3 months.





Information
regarding stock options and warrants outstanding and exercisable is summarized
as follows at September 30, 2010:





Warrants
                                                        
                                                        WarrantsAnd
                                                        
                                                        AndOptions
                                                        
                                                        OptionsExercise
                                                        
                                                        Outstanding
                                                        
                                                        ExercisablePrices
                                                        
                                                        (Shares)
                                                        
                                                        (Shares)$
                                                        0.333
                                                        
                                                        
                                                        1,566,626
                                                        
                                                        
                                                        1,566,626$
                                                        0.500
                                                        
                                                        
                                                        7,535,800
                                                        
                                                        
                                                        7,340,400$
                                                        0.650
                                                        
                                                        
                                                        120,000
                                                        
                                                        
                                                        120,000$
                                                        0.750
                                                        
                                                        
                                                        5,625,000
                                                        
                                                        
                                                        5,625,000$
                                                        1.000
                                                        
                                                        
                                                        2,050,000
                                                        
                                                        
                                                        1,550,000$
                                                        1.250
                                                        
                                                        
                                                        50,000
                                                        
                                                        
                                                        50,000$
                                                        1.650
                                                        
                                                        
                                                        200,000
                                                        
                                                        
                                                        100,00017,147,426
                                                        
                                                        
                                                        16,352,026





Outstanding
options and warrants to acquire 625,000 shares of the Company’s common stock had
not vested at September 30, 2010. At September 30, 2010, warrants and options
exercisable do not include warrants to acquire 170,400 shares of common stock
that are contingent upon the exercise of warrants contained in units sold as
part of the third private placement (see Note 4).




10.  Commitments and
Contingencies





Effective
March 22, 2006, the Company entered into a CRADA, as amended, with the NINDS of
the NIH. The CRADA is for a term of 66 months from the effective date and can be
unilaterally terminated by either party by providing written notice within sixty
days. The CRADA provides for the collaboration between the parties in the
identification and evaluation of agents that target the Nuclear Receptor
CoRepressor (N-CoR) pathway for glioma cell differentiation. The CRADA also
provides that NINDS and the Company will conduct research to determine if
expression of N-CoR correlates with prognosis in glioma patients. Pursuant to
the CRADA, the Company initially agreed to provide funds under the CRADA in the
amount of $200,000 per year to fund two technical assistants for the technical,
statistical and administrative support for the research activities, as well as
to pay for supplies and travel expenses. The first $200,000 was due within 180
days of the effective date and was paid in full on July 6, 2006. The second
$200,000 was paid in full on June 29, 2007. In June 2008, the CRADA was extended
to September 30, 2009, with no additional funding required for the period
between July 1, 2008 and September 30, 2008. For the period from October 1, 2008
through September 30, 2009, the Company agreed to provide additional funding
under the CRADA of $200,000, to be paid in four quarterly installments of
$50,000, each commencing on October 1, 2008. The first and second quarterly
installments of $50,000 were paid on September 29, 2008 and March 5, 2009,
respectively. During August 2009, the Company entered into an
amendment to the CRADA to extend its term from September 30, 2009 through
September 30, 2011. Pursuant to such amendment, the Company has agreed to
aggregate payments of $100,000 in two installments of $50,000, payable on
October 1, 2010 and January 5, 2011, inclusive of any prior unpaid commitments.
The October 1, 2010 installment was paid on September 29, 2010.





On
February 5, 2007, the Company entered into a two-year agreement pursuant to
which the Company engaged Chem-Master to synthesize a compound designated as
“LB-1”, and any other compound synthesized by Chem-Master pursuant to the
Company’s request, which have potential use in treating a disease, including,
without limitation, cancers such as glioblastomas. Pursuant to the Chem-Master
Agreement, the Company agreed to reimburse Chem-Master for the cost of
materials, labor, and expenses for other items used in the synthesis process,
and also agreed to grant Chem-Master a five-year option to purchase shares of
the Company’s common stock. The Company has the right to terminate the
Chem-Master Agreement at any time during its term upon sixty days prior written
notice.




21




On
January 29, 2008, the Chem-Master Agreement was amended to extend its term to
February 15, 2014, and to expressly provide for the design and synthesis of a
new series of compounds designated as “LB-3”. Pursuant to the Chem-Master
Agreement, as amended, the Company reimbursed Chem-Master for the costs of
materials, labor and expenses aggregating $9,000 and $13,000 during the nine
months ended September 30, 2009 and 2010, respectively.  There were no
expenditures to Chem-Master under this agreement during the three months ended
September 30, 2009 and 2010.





Effective
as of September 19, 2008, the Company entered into an agreement with the NIH
providing the Company with an exclusive license for all patents submitted
jointly with the NIH under the CRADA. The agreement provided for an initial
payment of $25,000 to NIH within 60 days of September 19, 2008, and for a
minimum annual royalty of $30,000 on January 1 of each calendar year following
the year in which the CRADA is terminated. The agreement also provides for the
Company to pay specified royalties based on (i) net sales by the Company and its
sub-licensees, (ii) the achievement of certain clinical benchmarks, and (iii)
the granting of sublicenses. The Company paid the initial $25,000 obligation on
November 10, 2008 and charged the amount to general and administrative costs
during the year ended December 31, 2008. As of September 30, 2010, no additional
amounts were due pursuant to this agreement.





On March
17, 2010, the Company engaged Theradex to assist the Company in bringing LB-100
through the FDA approval process at a total estimated cost of $105,064, of which
$12,529 had been incurred as of September 30, 2010. As of September 30, 2010,
work was proceeding under this contract.





On April
15, 2010, the Company entered into an agreement with Ascentage Pharma Group to
assist in the pharmacological characterization of the Company’s proprietary
compounds at a total estimated cost of $30,000. As of September 30, 2010,
$27,000 of this amount had been incurred and work was proceeding. During the
quarter ended September 30, 2010, the Company entered into a second agreement
with Ascentage Pharma Group at a total estimated cost of $35,000. As of
September 30, 2010, $14,500 of this amount had been incurred and work was
proceeding. Ascentage Pharma Group is an offshoot of Ascenta Therapeutics, of
which Dr. Mel Sorensen, a director of the Company, is the President and Chief
Executive Officer and a director.  Ascentage Pharma Group and Ascenta
Therapeutics have a continuing business relationship and certain common
shareholders.  However, Dr. Sorensen does not have any direct business
relationship with or ownership in Ascentage Pharma Group.





The
following table sets forth the Company’s principal cash obligations and
commitments for the next five fiscal years as of September 30, 2010 aggregating
$408,931, of which $218,396 is included in current liabilities in the
consolidated balance sheet at September 30, 2010.  Amounts included in
the 2010 column represent amounts due at September 30, 2010 for the remainder of
the 2010 fiscal year ending December 31, 2010.





Payments Due By YearTotal
                            
                            
                            2010
                            
                            
                            2011CRADA
                            
                            $
                            50,000
                            
                            
                            $
                            —
                            
                            
                            $
                            50,000Research
      and development contracts
                            
                            
                            179,714
                            
                            
                            
                            179,714
                            
                            
                            
                            —Consulting
      agreement with related party
                            
                            
                            12,500
                            
                            
                            
                            12,500
                            
                            
                            
                            —Liquidated
      damages payable under registration rights agreement
                            
                            
                            74,000
                            
                            
                            
                            74,000
                            
                            
                            
                            —Due
      to stockholder
                            
                            
                            92,717
                            
                            
                            
                            92,717
                            
                            
                            
                            —Total
                            
                            $
                            408,931
                            
                            
                            $
                            358,931
                            
                            
                            $
                            50,000




22




ITEM
      2.
            MANAGEMENT’S
      DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
      OPERATIONS





Overview




On June
30, 2006, Lixte Biotechnology, Inc., a privately held Delaware corporation
(“Lixte”) incorporated on August 9, 2005, completed a reverse merger transaction
with SRKP 7, Inc. (“SRKP”), a non-trading public shell company, whereby Lixte
became a wholly-owned subsidiary of SRKP. On December 7, 2006, SRKP amended its
Certificate of Incorporation to change its name to Lixte Biotechnology Holdings,
Inc. (“Holdings”).  Unless the context indicates otherwise, Lixte and
Holdings are hereinafter referred to as the “Company”.




For
financial reporting purposes, Lixte was considered the accounting acquirer in
the merger and the merger was accounted for as a reverse merger. Accordingly,
the historical financial statements presented herein are those of Lixte. The
stockholders’ equity section of SRKP has been retroactively restated for all
periods presented to reflect the accounting effect of the reverse merger
transaction. All costs associated with the reverse merger transaction were
expensed as incurred.




The
Company is considered a “development stage company” under current accounting
standards, as it has not yet commenced any revenue-generating operations, does
not have any cash flows from operations, and is dependent on debt and equity
funding to finance its operations.




The
Company’s common stock was listed for trading on the OTC Bulletin Board
commencing September 24, 2007 under the symbol “LIXT”.




Recent
Developments




In
January and February 2010, the Company raised $1,787,500 and $500,000,
respectively, through the sale of its securities.





In
September 2010, the National Cancer Institute (NCI), National Institutes of
Health (NIH), National Cancer Institute Experimental Therapeutics (NExT) Program
Senior Advisory Committee (SAC), Division of Cancer Treatment and Diagnosis
(DCTD), signed a Next Material Transfer Agreement formalizing a collaboration
with the Company for clinical evaluation of LB-100, one of the Company’s lead
anti-cancer compounds.





This
collaboration is a milestone-based approach in which NCI will first confirm
studies of the LB-100 compound in an animal model of glioblastoma multiforme,
the most common brain tumor of adults, and conduct an initial exploratory
toxicology study in an animal model.  At milestone intervals, the SAC will
re-evaluate project progress before considering assignment of additional support
and resources to this project.





The
mission of the NCI NExT Program is to advance clinical practice and bring
improved therapies to patients with cancer by supporting the most promising new
drug discovery and development projects.  The NCI partners with
successful applicants to facilitate the milestone-driven progression of new
anticancer drugs (small molecules, biologics) and imaging agents towards
clinical evaluation and registration.





The
advice and practical assistance of the NCI and its collaborators have the
potential to expedite evaluation of the clinical potential of
LB-100.  The research under the NExT Program will focus on the
pre-clinical evaluation of LB-100 that is needed for submission of an
application to the FDA for approval to assess LB-100 in a Phase I clinical
trial.





Going
Concern





The
Company’s consolidated financial statements have been presented on the basis
that it is a going concern, which contemplates the realization of assets and
satisfaction of liabilities in the normal course of business. The Company is in
the development stage and has not generated any revenues from operations to
date, and does not expect to do so in the foreseeable future.  The
Company has experienced recurring operating losses and negative operating cash
flows since inception, and has financed its working capital requirements through
the recurring sale of its equity securities.  As a result, the
Company’s independent registered public accounting firm, in its report on the
Company’s 2009 consolidated financial statements, has raised substantial doubt
about the Company’s ability to continue as a going concern.




23




The
Company’s ability to continue as a going concern is dependent upon its ability
to develop additional sources of capital and to ultimately achieve sustainable
revenues and profitable operations. The Company’s condensed consolidated
financial statements do not include any adjustments that might result from the
outcome of these uncertainties.




At
September 30, 2010, the Company had not yet commenced any revenue-generating
operations. All activity through September 30, 2010 has been related to the
Company’s formation, capital raising efforts and research and development
activities. As such, the Company has yet to generate any cash flows from
operations, and is dependent on debt and equity funding from both related and
unrelated parties to finance its operations. Prior to June 30, 2006, the
Company’s cash requirements were funded by advances from the Company’s founder
aggregating $92,717.





Because
the Company is currently engaged in research at an early stage, it will likely
take a significant amount of time to develop any product or intellectual
property capable of generating revenues. As such, the Company’s business is
unlikely to generate any sustainable revenues in the next several years, and may
never do so. Even if the Company is able to generate revenues in the future
through licensing its technologies or through product sales, there can be no
assurance that the Company will be able to generate a profit.




The
Company’s activities for the remainder of 2010 will consist of continuing drug
discovery and development efforts. The Company’s primary goal is to take the
Company’s LB-100 compound through a Phase I clinical trial by December 31, 2011.
The Company believes that its current resources are adequate to fund operations
through 2011, at a level that will allow the continuation of the Company’s two
drug development programs currently in process and completion of the initial
Phase I trial of LB-100, if no unexpected delays occur in obtaining FDA
approval.





The
amount and timing of future cash requirements will depend on the pace of these
programs, particularly the completion of the Phase I trial of LB-100. After
completion of the Phase I trial, the next step will be to determine the
anti-cancer activity against a particular type of human cancer in Phase II
trials. To carry out Phase II trials, the Company anticipates that it will be
necessary to raise additional funds in late 2011 from a combination of debt or
equity financings, and/or the sale, licensing or joint venturing of its
intellectual properties. Market conditions present uncertainty as to the
Company’s ability to secure additional funds, as well as its ability to reach
profitability. There can be no assurances that the Company will be able to
secure additional financing, or obtain favorable terms on such financing if it
is available, or as to the Company’s ability to achieve positive earnings and
cash flows from operations. Continued negative cash flows and lack of liquidity
create significant uncertainty about the Company’s ability to fully implement
its operating plan beyond December 2011, as a result of which the Company may
have to reduce the scope of its planned operations. If cash resources are
insufficient to satisfy the Company’s liquidity requirements, the Company would
be required to scale back or discontinue its technology and product development
programs, or obtain funds, if available, through strategic alliances that may
require the Company to relinquish rights to certain of its technologies
products, or to discontinue its operations entirely.




Recent
Accounting Pronouncements




In April
2010, the Financial Accounting Standards Board (“FASB”) issued new accounting
guidance in applying the milestone method of revenue recognition to research or
development arrangements. Under this guidance, management may recognize revenue
contingent upon the achievement of a milestone in its entirety, in the period in
which the milestone is achieved, only if the milestone meets all of the criteria
within the guidance to be considered substantive. The new guidance is effective
on a prospective basis for research and development milestones achieved in
fiscal years beginning on or after June 15, 2010. Early adoption is permitted;
however, adoption of this guidance as of a date other than January 1, 2011 would
require the Company to apply this guidance retrospectively effective as of
January 1, 2010, and would require disclosure of the effect of this guidance as
applied to all previously reported interim periods in the fiscal year of
adoption. As the Company plans to implement this guidance prospectively, the
effect of this guidance will be limited to future transactions. The Company does
not expect that adoption of this guidance will have any impact on its financial
position or results of operations, as the Company does not have or currently
expect to have any research and development arrangements which will be accounted
for under the milestone method.





In
January 2010, the FASB issued new accounting guidance which requires new
disclosures regarding transfers in and out of Level 1 and Level 2 fair value
measurements, as well as requiring presentation on a gross basis of information
about purchases, sales, issuances and settlements in Level 3 fair value
measurements. The new guidance also clarifies existing disclosures regarding
level of disaggregation, inputs and valuation techniques. The new guidance is
effective for interim and annual reporting periods beginning after December 15,
2009.  Disclosures about purchases, sales, issuances and settlements in the
roll forward of activity in Level 3 fair value measurements are effective for
fiscal years beginning after December 15, 2010. As this guidance only requires
additional disclosure, the Company does not expect that adoption of this
guidance will have any impact on its financial position or results of
operations.




24


In April
2010, FASB issued new accounting guidance which addresses the classification of
a share-based payment award with an exercise price denominated in the currency
of a market in which the underlying equity security trades.  The new
guidance clarifies that a share-based payment award with an exercise price
denominated in the currency of a market in which a substantial portion of the
entity’s equity securities trades shall not be considered to contain a market,
performance, or service condition.   Therefore, such an award is
not to be classified as a liability if it otherwise qualifies as equity
classification.  The new guidance is effective for fiscal years, and
interim periods within those fiscal years, beginning on or after December 15,
2010.  The guidance will be applied by recording a cumulative-effect
adjustment to the opening balance of retained earnings for all outstanding
awards as of the beginning of the fiscal year in which the guidance is initially
applied.  The Company does not expect that the adoption of this
guidance will have any impact on its results of operations or financial
position.





Management
does not believe that any other recently issued, but not yet effective,
authoritative guidance, if currently adopted, would have a material impact on
the Company's financial statement presentation or disclosures.





Critical
Accounting Policies and Estimates




The
Company prepared its consolidated financial statements in accordance with
accounting principles generally accepted in the United States of America. The
preparation of these financial statements requires the use of estimates and
assumptions that affect the reported amounts of assets and liabilities and the
disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amount of revenues and expenses during the reporting
period. Management periodically evaluates the estimates and judgments made.
Management bases its estimates and judgments on historical experience and on
various factors that are believed to be reasonable under the circumstances.
Actual results may differ from these estimates as a result of different
assumptions or conditions.




The
following critical accounting policies affect the more significant judgments and
estimates used in the preparation of the Company’s consolidated financial
statements.





Research
and Development





Research
and development costs are expensed as incurred.  Research and
development expenses consist primarily of fees paid to consultants and outside
service providers, patent fees and costs, and other expenses relating to the
acquisition, design, development and testing of the Company's treatments and
product candidates.





Amounts
due, pursuant to contractual commitments, on research and development contracts
with third parties are recorded as a liability, with the related amount of such
contracts recorded as advances on research and development contract services on
the Company’s balance sheet. Such advances on research and development contract
services are expensed over their life on the straight-line basis, unless the
achievement of milestones, the completion of contracted work, or other
information indicates that a different expensing schedule is more
appropriate.  The Company reviews the status of its research and
development contracts on a quarterly basis.





Patent
Costs





Due to
the significant uncertainty associated with the successful development of one or
more commercially viable products based on the Company's research efforts and
any related patent applications, all patent costs, including patent-related
legal and filing fees, are expensed as incurred.





Stock-Based
Compensation





The
Company periodically issues stock options and warrants to officers, directors
and consultants for services rendered. Options vest and expire according to
terms established at the grant date.





The
Company accounts for share-based payments to officers and directors by measuring
the cost of services received in exchange for equity awards based on the grant
date fair value of the awards, with the cost recognized as compensation expense
in the Company’s financial statements over the vesting period of the
awards.





The
Company accounts for share-based payments to consultants by determining the
value of the stock compensation based upon the measurement date at either (a)
the date at which a performance commitment is reached or (b) at the date at
which the necessary performance to earn the equity instruments is
complete.





Options
granted to Scientific Advisory Board committee members and outside consultants
are revalued each reporting period to determine the amount to be recorded as an
expense in the respective period. As the options vest, they are valued on each
vesting date and an adjustment is recorded for the difference between the value
already recorded and the then current value on the date of vesting.




25




The fair
value of stock-based compensation is affected by several variables, the most
significant of which are the life of the equity award, the exercise price of the
security as compared to the fair market value of the common stock on the grant
date, and the estimated volatility of the common stock over the term of the
equity award.





Income
Taxes





The
Company accounts for income taxes under an asset and liability approach for
financial accounting and reporting for income taxes. Accordingly, the Company
recognizes deferred tax assets and liabilities for the expected impact of
differences between the financial statements and the tax basis of assets and
liabilities.





The
Company records a valuation allowance to reduce its deferred tax assets to the
amount that is more likely than not to be realized. In the event the Company was
to determine that it would be able to realize its deferred tax assets in the
future in excess of its recorded amount, an adjustment to the deferred tax
assets would be credited to operations in the period such determination was
made. Likewise, should the Company determine that it would not be able to
realize all or part of its deferred tax assets in the future, an adjustment to
the deferred tax assets would be charged to operations in the period such
determination was made.





Plan
of Operation





General
Overview of Plans





The
Company’s original focus was the development of new treatments for the most
common and most aggressive type of brain cancer of adults, glioblastoma
multiforme (“GBM”), and the most common cancer of children, neuroblastoma. The
Company has expanded the scope of its anti-cancer investigational activities to
include the most common brain tumor of children, medulloblastoma, and also to
several other types of more common cancers. This expansion of activity is based
on documentation that each of two distinct types of drugs being developed by the
Company has activity against cell lines of breast, colon, lung, prostate,
pancreas, ovary, stomach and liver cancer, as well as against the major types of
leukemias. LB-100 has now been shown to have activity in animal models of brain
tumors of adults and children, and also against melanomas and
sarcomas.  Studies in animal models of human melanoma, lymphoma,
sarcoma, brain tumors, and the rare neuroendocrine cancer, pheochromocytoma,
have demonstrated marked potentiation by LB-100 of the anti-tumor activity of
the widely used standard chemotherapeutic drugs. These studies confirm that the
LB-100 compounds, combined with any of several “standard anti-cancer drugs”,
have broad activity, affecting many different cell types of cancer. This is
unusual and important because these compounds may be useful for treatment of
cancer in general.





The
research on brain tumors is proceeding in collaboration with the National
Institute of Neurological Disorders and Stroke (“NINDS”) of the National
Institutes of Health (“NIH”) under a Cooperative Research and Development
Agreement (“CRADA”) entered into on March 22, 2006, as amended. The research at
NINDS continues to be led by Dr. Zhengping Zhuang, an internationally recognized
investigator in the molecular pathology of cancer. Dr. Zhuang is aided by two
senior research technicians supported by the Company as part of the CRADA. The
goal of the CRADA is to develop more effective drugs for the treatment of GBM
through the processes required to gain Food and Drug Administration (“FDA”)
approval for clinical trials. The Company has entered into an amendment to the
CRADA to extend its term from September 30, 2009 through September 30,
2011.





During
2009, the Company signed material transfer agreements with academic
investigators at major cancer centers in the United States, as well as with one
investigator in China with a unique animal model of a sarcoma, to expand
molecular and applied studies of the anti-cancer activity of the Company’s
compounds.  The Company retained the right to all discoveries made in
these studies.





The
Company’s longer-term goal is to secure one or more strategic partnerships with
pharmaceutical companies with major programs in cancer, anti-fungal treatments,
and/or neuroprotective measures. The Company’s immediate focus has shifted to
obtaining approval from the FDA to carry a lead compound of the LB-100 series
into clinical trial. The Company believes the potent activity of these drugs in
combination with standard non-specific chemotherapeutic drugs against a diverse
array of common and uncommon cancers of adults and children merits bringing this
treatment to patients as rapidly as reasonably possible. In addition, the
demonstration of clinical benefit would be important to potential investors and
to large pharmaceutical companies looking to add an entirely new approach to
their anti-cancer drug pipelines.





The
significant diversity of the potential therapeutic value of the Company’s
compounds stems from the fact that these agents modify critical pathways in
cancer cells and in microorganisms such as fungi and appear to ameliorate
pathologic processes that lead to brain injury caused by trauma or toxins or
through as yet unknown mechanisms that underlie the major chronic neurologic
diseases, including Alzheimer’s Disease, Parkinson’s Disease, and Amyotrophic
Lateral Sclerosis (ALS, or Lou Gehrig’s Disease).  Studies of the
potential neuroprotective effects of homologs of each class of the Company’s
compounds are continuing under a contract with Southern Research Institute,
Birmingham, Alabama.




26




Plans
for 2010 and Beyond





The
Company’s primary objective is to complete studies needed for a successful
application to the FDA for an Investigational New Drug (“IND”) for the clinical
evaluation of LB-100 by the end of the first quarter of 2011. The estimated cost
for drug synthesis formulation, pharmacokinetic, and toxicologic studies needed
for an IND application is currently estimated at approximately $1,200,000
Accordingly, the Company believes that it currently has sufficient capital to
fund its operations, including the continued development of the LB-200 series
and the sponsorship of a Phase I clinical trial of LB-100.





The
critical need for the next step in the clinical development of LB-100 is to
obtain IND approval from the FDA to administer the drug to patients. In order to
do this, the Company must demonstrate that LB-100 can be administered safely to
human beings at a dose and at a frequency that achieves the desired
pharmacologic effect, in this case inhibition of a specific enzyme, without
being associated with toxicities considered unacceptable. A compound that has a
mechanism of action similar to that of LB-100 has been given with safety and
benefit to cancer patients outside the United States in the past. This compound
has a chemical feature which appears to be responsible for most of its toxicity.
This feature has been removed from LB-100, making it likely that the Company’s
compound will be less toxic and, therefore, safer for human use.





With
current resources, the Company intends to further characterize the anti-cancer
and anti-fungal activity of certain homologs of drugs of the LB-200 series.
These studies would be done in collaboration with academic
partners.





Results
of Operations





The
Company is a development stage company and had not commenced revenue-generating
operations at September 30, 2010.





Three
Months Ended September 30, 2010 and 2009





General and Administrative
Costs.  For the three months ended September 30, 2010, general
and administrative costs were $246,037, which consisted of the vested portion of
the fair value of stock options issued to directors and consultants of $194,493,
consulting and professional fees of $36,601, insurance expense of $6,125, stock
transfer fees of $2,149, travel and entertainment costs of $4,065, and other
operating costs of $2,604.





For the
three months ended September 30, 2009, general and administrative costs were
$300,850, which consisted of the vested portion of the fair value of stock
options issued to directors and consultants of $231,282, consulting and
professional fees of $55,968, insurance expense of $5,984, stock transfer fees
of $2,231, travel and entertainment costs of $893, and other operating costs of
$4,492.





Depreciation.  There
was no depreciation expense for the three months ended September 30, 2010 and
2009.





Research and Development
Costs.  For the three months ended September 30, 2010, research
and development costs were $132,656, which consisted of the vested portion of
the fair value of stock options issued to a consultant and a vendor of $63,513,
patent costs of $22,806, third-party contractor costs of $40,087, and consulting
fees to a related party of $6,250.





For the
three months ended September 30, 2009, research and development costs were
$152,235, which consisted of the vested portion of the fair value of stock
options issued to a consultant and a vendor of $19,236, patent costs of
$107,999, and third-party contractor costs of $25,000.





Interest
Income.  For the three months ended September 30, 2010 and
2009, interest income was $700 and $31, respectively.





Net
loss.  For the three months ended September 30, 2010, the
Company incurred a net loss of $377,993, as compared to a net loss of $453,054
for the three months ended September 30, 2009.





Nine
Months Ended September 30, 2010 and 2009





General and Administrative
Costs.  For the nine months ended September 30, 2010, general
and administrative costs were $511,506, which consisted of the vested portion of
the fair value of stock options issued to directors and consultants of $287,767,
consulting and professional fees of $172,437, insurance expense of $18,375,
stock transfer fees of $6,860, travel and entertainment costs of $13,326, and
other operating costs of $12,741.




27




For the
nine months ended September 30, 2009, general and administrative costs were
$555,743, which consisted of the vested portion of the fair value of stock
options issued to directors and consultants of $306,692, consulting and
professional fees of $204,958, insurance expense of $17,894, stock transfer fees
of $7,104, travel and entertainment costs of $3,307, and other operating costs
of $15,788.





Depreciation.  For
the nine months ended September 30, 2009, depreciation expense was
$128.  There was no depreciation expense for the nine months ended
September 30, 2010.





Research and Development
Costs.  For the nine months ended September 30, 2010, research
and development costs were $527,634, which consisted of the vested portion of
the fair value of stock options issued to a consultant and a vendor of $81,640,
patent costs of $193,586, third-party contractor costs of $227,951, laboratory
supplies of $13,000, and consulting fees to a related party of
$11,457.





For the
nine months ended September 30, 2009, research and development costs were
$419,341, which consisted of the vested portion of the fair value of stock
options issued to a consultant and a vendor of $116,835, patent costs of
$154,506, third-party contractor costs of $139,000, and laboratory supplies of
$9,000.





Interest
Income.  For the nine months ended September 30, 2010 and 2009,
interest income was $1,249 and $83, respectively.





Net
loss.  For the nine months ended September 30, 2010, the
Company incurred a net loss of $1,037,891, as compared to a net loss of $975,581
for the nine months ended September 30, 2009.





Liquidity
and Capital Resources – September 30, 2010





The
Company’s consolidated financial statements have been presented on the basis
that it is a going concern, which contemplates the realization of assets and
satisfaction of liabilities in the normal course of business. The Company is in
the development stage and has not generated any revenues from operations to
date, and does not expect to do so in the foreseeable future.  The
Company has experienced recurring operating losses and negative operating cash
flows since inception, and has financed its working capital requirements through
the recurring sale of its equity securities.  As a result, the
Company’s independent registered public accounting firm, in its report on the
Company’s 2009 consolidated financial statements, has raised substantial doubt
about the Company’s ability to continue as a going concern (see “Going Concern”
above”).




The
Company’s activities for the remainder of 2010 will consist of continuing drug
discovery and development efforts. The Company’s primary goal is to take the
Company’s LB-100 compound through a Phase I clinical trial by December 31, 2011.
The Company believes that its current resources are adequate to fund operations
through 2011, at a level that will allow the continuation of the Company’s two
drug development programs currently in process and completion of the initial
Phase I trial of LB-100, if no unexpected delays occur in obtaining FDA
approval.




Operating
Activities.  For the nine months ended September 30, 2010,
operating activities utilized cash of $732,580, as compared to utilizing cash of
$497,000 for the nine months ended September 30, 2009.




At
September 30, 2010, the Company had working capital of $1,720,098, as compared
to working capital of $1,301,082 at December 31, 2009. The increase in working
capital at September 30, 2010 as compared to December 31, 2009 was due primarily
to the sale of the Company’s securities pursuant to two private placements
occurring in January and February 2010 that generated net proceeds of
$1,087,500, net of $1,200,000 of advances on such financing being received in
December 2009.





Investing
Activities.  For the nine months ended September 30, 2010,
investing activities consisted of $1,775,822 of cash placed into a money market
fund. There were no investing activities during the nine months ended September
30, 2009.





Financing
Activities.  For the nine months ended September 30, 2010,
financing activities provided net cash of $1,087,500, consisting of the gross
proceeds from the sale of securities of $2,287,500, less $1,200,000 of advances
received through December 31, 2009. For the nine months ended September 30,
2009, financing activities provided net cash of $597,050, consisting of the
gross proceeds from the sale of common stock of $710,000, reduced by the payment
of private placement offering costs of $112,950, the repayment of a note payable
to a consultant of $100,000, and the $100,000 proceeds of a new borrowing from
the consultant.




28




Principal
Commitments





Effective
March 22, 2006, the Company entered into a CRADA, as amended, with the NINDS of
the NIH. The CRADA is for a term of 66 months from the effective date and can be
unilaterally terminated by either party by providing written notice within sixty
days. The CRADA provides for the collaboration between the parties in the
identification and evaluation of agents that target the Nuclear Receptor
CoRepressor (N-CoR) pathway for glioma cell differentiation. The CRADA also
provides that NINDS and the Company will conduct research to determine if
expression of N-CoR correlates with prognosis in glioma patients. Pursuant to
the CRADA, the Company initially agreed to provide funds under the CRADA in the
amount of $200,000 per year to fund two technical assistants for the technical,
statistical and administrative support for the research activities, as well as
to pay for supplies and travel expenses. The first $200,000 was due within 180
days of the effective date and was paid in full on July 6, 2006. The second
$200,000 was paid in full on June 29, 2007. In June 2008, the CRADA was extended
to September 30, 2009, with no additional funding required for the period
between July 1, 2008 and September 30, 2008. For the period from October 1, 2008
through September 30, 2009, the Company agreed to provide additional funding
under the CRADA of $200,000, to be paid in four quarterly installments of
$50,000, each commencing on October 1, 2008. The first and second quarterly
installments of $50,000 were paid on September 29, 2008 and March 5, 2009,
respectively. During August 2009, the Company entered into an
amendment to the CRADA to extend its term from September 30, 2009 through
September 30, 2011.  Pursuant to such amendment, the Company has
agreed to aggregate payments of $100,000 in two installments of $50,000, payable
on October 1, 2010 and January 5, 2011, inclusive of any prior unpaid
commitments. The October 1, 2010 installment was paid on September 29,
2010.





On
February 5, 2007, the Company entered into a two-year agreement pursuant to
which the Company engaged Chem-Master to synthesize a compound designated as
“LB-1”, and any other compound synthesized by Chem-Master pursuant to the
Company’s request, which have potential use in treating a disease, including,
without limitation, cancers such as glioblastomas. Pursuant to the Chem-Master
Agreement, the Company agreed to reimburse Chem-Master for the cost of
materials, labor, and expenses for other items used in the synthesis process,
and also agreed to grant Chem-Master a five-year option to purchase shares of
the Company’s common stock. The Company has the right to terminate the
Chem-Master Agreement at any time during its term upon sixty days prior written
notice.





On
January 29, 2008, the Chem-Master Agreement was amended to extend its term to
February 15, 2014, and to expressly provide for the design and synthesis of a
new series of compounds designated as “LB-3”. Pursuant to the Chem-Master
Agreement, as amended, the Company reimbursed Chem-Master for the costs of
materials, labor and expenses aggregating $9,000 and $13,000 during the nine
months ended September 30, 2009 and 2010, respectively.  There were no
expenditures to Chem-Master under this agreement during the three months ended
September 30, 2009 and 2010.





Effective
as of September 19, 2008, the Company entered into an agreement with the NIH
providing the Company with an exclusive license for all patents submitted
jointly with the NIH under the CRADA. The agreement provided for an initial
payment of $25,000 to NIH within 60 days of September 19, 2008, and for a
minimum annual royalty of $30,000 on January 1 of each calendar year following
the year in which the CRADA is terminated. The agreement also provides for the
Company to pay specified royalties based on (i) net sales by the Company and its
sub-licensees, (ii) the achievement of certain clinical benchmarks, and (iii)
the granting of sublicenses. The Company paid the initial $25,000 obligation on
November 10, 2008 and charged the amount to general and administrative costs
during the year ended December 31, 2008. As of September 30, 2010, no additional
amounts were due pursuant to this agreement.





On March
17, 2010, the Company engaged Theradex to assist the Company in bringing LB-100
through the FDA approval process at a total estimated cost of $105,064, of which
$12,529 had been incurred as of September 30, 2010. As of September 30, 2010,
work was proceeding under this contract.





On April
15, 2010, the Company entered into an agreement with Ascentage Pharma Group to
assist in the pharmacological characterization of the Company’s proprietary
compounds at a total estimated cost of $30,000. As of September 30, 2010,
$27,000 of this amount had been incurred and work was proceeding. During the
quarter ended September 30, 2010, the Company entered into a second agreement
with Ascentage Pharma Group at a total estimated cost of $35,000. As of
September 30, 2010, $14,500 of this amount had been incurred and work was
proceeding. Ascentage Pharma Group is an offshoot of Ascenta Therapeutics, of
which Dr. Mel Sorensen, a director of the Company, is the President and Chief
Executive Officer and a director.  Ascentage Pharma Group and Ascenta
Therapeutics have a continuing business relationship and certain common
shareholders.  However, Dr. Sorensen does not have any direct business
relationship with or ownership in Ascentage Pharma Group.





The
following table sets forth the Company’s principal cash obligations and
commitments for the next five fiscal years as of September 30, 2010 aggregating
$408,931, of which $218,396 is included in current liabilities in the
consolidated balance sheet at September 30, 2010.  Amounts included in
the 2010 column represent amounts due at September 30, 2010 for the remainder of
the 2010 fiscal year ending December 31, 2010.




29




Payments Due By YearTotal
                          
                          
                          2010
                          
                          
                          2011CRADA
                          
                          $
                          50,000
                          
                          
                          $
                          —
                          
                          
                          $
                          50,000Research
      and development contracts
                          
                          
                          179,714
                          
                          
                          
                          179,714
                          
                          
                          
                          —Consulting
      agreement with related party
                          
                          
                          12,500
                          
                          
                          
                          12,500
                          
                          
                          
                          —Liquidated
      damages payable under registration rights agreement
                          
                          
                          74,000
                          
                          
                          
                          74,000
                          
                          
                          
                          —Due
      to stockholder
                          
                          
                          92,717
                          
                          
                          
                          92,717
                          
                          
                          
                          —Total
                          
                          $
                          408,931
                          
                          
                          $
                          358,931
                          
                          
                          $
                          50,000




Off-Balance
Sheet Arrangements





At
September 30, 2010, the Company did not have any transactions, obligations or
relationships that could be considered off-balance sheet
arrangements.




30




ITEM 3.
            QUANTITATIVE
      AND QUALITATIVE DISCLOSURE ABOUT MARKET
RISK





Not
applicable.





ITEM 4.
            CONTROLS
      AND PROCEDURES





(a)
Evaluation of Disclosure Controls and Procedures





The
Company carried out an evaluation, under the supervision and with the
participation of its management, including its principal executive officer and
principal financial officer (who is the same individual), of the effectiveness
of the Company’s disclosure controls and procedures (as
defined  in  Rules  13a-15(e) and 15d-15(e) of
the  Exchange  Act (defined  below)). Based upon
that evaluation, the Company’s principal executive officer and principal
financial officer concluded that, as of the end of the period covered in this
report, the Company’s disclosure controls and procedures were effective to
ensure that information required to be disclosed in reports filed under the
Securities Exchange Act of 1934, as amended (the "Exchange Act"), is recorded,
processed, summarized and reported within the required time periods and is
accumulated and communicated to the Company’s management, including the
Company’s principal executive officer and principal financial officer, as
appropriate, to allow timely decisions regarding required
disclosure.





The
Company’s management, including its principal executive officer and principal
financial officer, does not expect that its disclosure controls and procedures
or its internal controls will prevent all error or fraud.  A control
system, no matter how well conceived and operated, can provide only
reasonable, not absolute, assurance that the objectives of the control system
are met. Further, the design of a control system must reflect the fact that
there are resource constraints and the benefits of controls must be considered
relative to their costs.  Due to the inherent limitations in all control
systems, no evaluation of controls can provide absolute assurance that all
control issues and instances of fraud, if any, have been detected. Accordingly,
management believes that the financial statements included in this report fairly
present in all material respects the Company’s financial condition, results of
operations and cash flows for the periods presented.





(b)
Changes in Internal Controls Over Financial Reporting





In
addition, the Company’s management, with the participation of its principal
executive officer and principal financial officer, has determined that no change
in the Company’s internal control over financial reporting (as that term is
defined in Rules 13(a)-15(f) and 15(d)-15(f) of the Securities Exchange Act of
1934) occurred during or subsequent to the end of the period covered in this
report that has materially affected, or is reasonably likely to materially
affect, the Company’s internal control over financial reporting.




31




PART
II - OTHER INFORMATION




ITEM
      1.
            LEGAL
      PROCEEDINGS





The
Company is currently not a party to any pending or threatened legal
proceedings.





ITEM
      1A.
            RISK
      FACTORS





Not
applicable.




ITEM
      2.
            UNREGISTERED
      SALES OF EQUITY SECURITIES AND USE OF
PROCEEDS





Not
applicable.





ITEM
      3.
            DEFAULTS
      UPON SENIOR SECURITIES





Not
applicable.




ITEM
      4.
            RESERVED





Not
applicable.




ITEM
      5.
            OTHER
      INFORMATION





Not
applicable.





ITEM
      6.
            EXHIBITS





A list of
exhibits required to be filed as part of this report is set forth in the Index
to Exhibits, which is presented elsewhere in this document, and is incorporated
herein by reference.




32




SIGNATURES





In
accordance with the requirements of the Securities and Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.





LIXTE
      BIOTECHNOLOGY HOLDINGS, INC.(Registrant)Date: 
      November 3, 2010
                By:
                /s/ JOHN
      S. KOVACHJohn
      S. KovachChief
      Executive Officer and
                  Chief
      Financial Officer(Principal
      financial and accounting
officer)




33




INDEX TO
EXHIBITS





Exhibit
                  Number
                
                Description of Document31.1
                
                Officer’s
      Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
      (1)32.1
                
                Officer’s
      Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
      (1)





(1)
            Filed
      herewith.




34